CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

CABS BioPacific Conference 2021

Passion for Better Medicine

Leading Biotechnology and Innovation

2021 BioPacific Conference - Virtual

22nd Annual Conference of CABS

8:30AM - 4:30PM PDT, October 30, 2021



Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

CABS Contact Information
（联系信息）

Mailing Address（邮政地址）
268 Bush Street, #1888
San Francisco, CA 94104, USA

Website（网页地址）
http://www.cabsweb.org

Email（电子邮件信箱）
General information
（一般信息）:
Info@CABSweb.org

Membership（会员申请）:
Membership@CABSweb.org

Fundraising（募捐）:
Fundraising@CABSweb.org

Brochure Design
（会议手册设计）
Xiaojun Li

Brochure Production
（会议手册制作）
CABS Publication Committee 2021
CABS Leadership

2021 BIOPACIFIC CONFERENCE

Passion for Better Medicine

TABLE OF CONTENTS

**The official working language of the conference is English*

Chinese American Biopharmaceutical Society (CABS)
2021 BioPacific Conference Sponsors

Diamond Sponsors

apollomics 冠科美博

BIOSYSTEMS Acro

HKSTP 香港科技園

10 Years Long-Term Platinum Sponsor

MORRISON FOERSTER

KENSON VENTURES LLC

Platinum Sponsors

GenScript Make Research Easy

江苏无锡（惠山）生命科技产业园 L-PARK

HANHAI BIOLABS

BIOCYTOGEN

HANHAI Silicon Valley 瀚海硅谷中心

Gold Sponsors

CR MedIcon A PHARMARON COMPANY

BIORTUS

X-THERMA

Q BAY center 钱塘中心

JJLAKE BUSINESS CENTER

Silver Sponsors

NVIGEN Nano Vision · Life Science

Accurus Biosciences

FRONTAGE

ProMab Biotechnologies, Inc.

Bellen

AD Studio

3H Science Essentials Pharmaceutical analysis

Badge Sponsor

EUREKA THERAPEUTICS

Our Vision

- *To serve as the gateway linking life science professionals & organizations in the U.S. & Pacific Rim Countries*

Our Mission

- *To SERVE life science professionals to promote professional interactions locally and across the Pacific*
- *To FOSTER business opportunities and exchanges in the life science industry between the U.S. and Pacific Rim countries*
- *To PROMOTE public awareness of progress and development in the life sciences industry*
- *To COLLABORATE with other organizations in areas of mutual interest*

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会

WHO WE ARE

The Chinese American Biopharmaceutical Society (CABS) is a non-profit organization for professionals in the biopharmaceutical industry. CABS is headquartered in San Francisco Bay Area, California. This is the home of the Silicon Valley, the birthplace of biotechnology and one of the largest biomedical clusters with the highest venture capital investment in the world. There are more than a thousand biopharmaceutical/biotech companies in this area, including several large biopharmaceuticals such as Amgen, Genentech and Gilead. CABS is a highly influential association with more than 3000 members and subscribers in the life sciences industry. About 70% of our members have PhD degrees relating to life sciences. A considerable proportion of the members hold senior research and management positions in US-based and multi-national life sciences corporations. Many of our members are experts and leaders, innovative entrepreneurs, lawyers and venture capitalists or investors in the life sciences sector. CABS is the largest and most active Chinese biopharmaceutical association in North America. We organize many activities to promote international collaborations in life sciences and to provide Science & Technology Parks and life sciences companies in Asia Pacific countries with an excellent platform to promote business and to recruit talent. In addition to year-round technology and business seminars, the annual BioPacific Conference organized by CABS is a highly anticipated event that attracts hundreds of biopharmaceutical professionals and business leaders.

WELCOME

Yang Tian, PhD
President of CABS

Remarks from the President of Chinese American BioPharmaceutical Society (CABS)

On behalf of everyone at CABS, I would like to express our sincere gratitude to all the speakers and sponsors for their support of our association and this conference. Special thanks to President-elect and the 2021 BioPacific Conference Organizing Committee Chair, Dr. Carrie Wang, the Conference Organizing Committee members, and all the volunteers for their passion, dedication, diligence and hard work to make this conference possible and successful.

From 2020 to 2021, the outbreak of coronavirus disease 2019 (COVID-19) have created unprecedented challenges for public health, societies, and economies around the world. At the center of global attention, the entire biopharma industry has been at the front-line of fighting the pandemic and also has its own challenges, such as employee safety, supply chain disruption, shortage of raw materials and delayed clinical trials. Despite those challenges, the biopharma industry has made remarkable deliverables during the pandemic. From highly efficacious vaccines to antiviral therapeutics and diagnostics, the biopharma industry has done all that within unprecedented time frames with vigorous sciences behind those medicines fighting against COVID-19. At the same time, it has not slowed down its innovation engines to find new treatments and cures for other diseases. US FDA approved a total of 53 New Chemical Entities in 2020, plus 37 approved by September, 2021, a number that is no less than any year pre-pandemic.

Many members of CABS community fought against the pandemic not only as the front-line healthcare workers but also as biopharma/academic professionals to continue preclinical and clinical research and development, prevent drug shortages, and secure supply chains. In response to the global shortage of Personal Protective Equipment (PPE) to protect our healthcare workers, members of CABS community have donated and helped sourcing PPEs for hospitals in both US and China. Here I want to express our greatest respect and gratitude to members of CABS community who have participated in global fight against COVID-19.

It is our great honor to recognize the extraordinary achievements of Dr. John O. Link and Dr. Xian-Ping Lu, the awardees of 2021 CABS Ken Fong Award in Life Sciences. Dr. Link is awarded for his achievements in the discovery of antiviral therapies for both HCV and HIV that have changed many patient's life. Dr. Lu is awarded for his entrepreneurship to bring Chipscreen Biosciences into one of China's most innovative and vertically integrated biopharma companies. We also appreciate both awardees' continuous support of CABS in the past years and in the future.

For the past 23 years, CABS has been one of the largest and most active non-profit biopharma organizations in San Francisco/Bay Area. It has been such an honor and privilege to serve as President and to work with 2019-2021 CABS Executive Council (EC) and the volunteers. Due to COVID-19 pandemic, they are the first CABS EC team that served two terms in a roll. Here I want to express my greatest appreciation to their efforts. In the two years, this team successfully organized more than 30 high-quality events with total attendees greater than 60,000. By going virtual, CABS events can now reach to audiences from more than 30 countries around the world. Those events included the CABS signature forum "2020 CABS Investor Forum" and "2021 CABS Investor Forum" during JP Morgan Healthcare Conference, symposiums on "Gene therapy", "Antibody Drug Conjugate", "Oligo-therapeutics", and seminars/panel discussions on COVID-19 therapeutics, vaccine, contact tracing and diagnostics, which are all very well received. We will continue to offer more opportunities for life science professionals to learn and network. Once again, thank you all for the unyielding support! Please enjoy 2021 BioPacific Conference!

Yang Tian, PhD
President of CABS



Carrie Wang, MD
Chair of 2021 BioPacific Conference Organizing Committee, President-elect of CABS

Remarks from the Chair of 2021 BioPacific Conference Organizing Committee

I am pleased to welcome everybody to the 2021 BioPacific Conference! It is my honor and privilege to serve as Organizing Committee Chair. It has been a great pleasure to work with everyone involved in the organization of the 2021 BioPacific Conference. I would like to thank all our volunteers for making this conference possible, especially with the challenges of the ongoing COVID-19 pandemic. This is the first conference in the history of CABS to be completely conducted on a digital platform.

The theme of the 2021 BioPacific Conference is Passion for Better Medicine - Leading Biotechnology and Innovation. This unique theme is particularly relevant to what is happening in the academic world and the biopharmaceutical industry in 2021. The conference will cover broad topics on cutting-edge science and technology including gene therapy, cell therapy, next generation cancer immunotherapy, AI technology for drug development, status review of the COVID-19 pandemic, latest developments in biopharmaceutical policies and regulations, legal considerations in life sciences, cross-border investment trends, strategic partnership and financing trends in the biotech industry during the COVID-19 pandemic. We will announce the winners of the 2021 CABS K. Fong Award in life sciences. Their discoveries and careers reshaped the biotech landscape in China and contributed to the development of first-in-class HIV drugs.

Given the many challenges we are facing due to the pandemic, I would like to express my gratitude to everyone for making this year's digital conference possible.

A big thank you to our 31 esteemed speakers. Each of them took time from their busy schedules and lives to share with us their expertise on some of the most exciting developments in biotech and the life sciences. Additionally, we are very grateful to have the support of 20 companies at our conference this year. The BioPacific Conference and other CABS events offer an excellent interactive platform to connect and engage with professionals and representatives of the industry – ranging from startups to global pharmaceutical companies. Lastly, I would like to once again thank and recognize our amazing team of volunteers. Thank you for working with passion and dedication to help bring this conference online. Without their commitment, none of this would have been possible.

We truly appreciate all your support for CABS and for being here with us today. We hope you enjoy the first fully digital CABS BioPacific Conference. Thank you all!



Carrie Wang, MD
Chair of 2021 BioPacific Conference Organizing Committee
President-elect of CABS

CABS Leadership

President-elect
Carrie Wang
ARC Medical Devices

President
Yang Tian
Gilead Sciences

Past-President
Yan Wang
Klus Pharma

Board of Directors

Yan Wang, PhD
Alex J. Zhang, PhD, MBA
Cheni Kwok, PhD, CLP
Jiangwen Majeti, PhD, MBA
Alan Hao, PhD
Zhonghua Pei, PhD
Wentao Zhang, PhD
Janet Xiao, PhD, JD
Shichang Miao, PhD
Jing-Shan Hu, PhD
Cheng Liu, PhD
John Wang, PhD

2021 Executive Council

Office of the President
- President: Yang Tian, PhD, Sr. Research Scientist, Gilead Sciences
- President-elect: Carrie Wang, MD, VP of Preclinical, ARC Medical Devices
- Past President: Yan Wang, PhD, Sr. Director of Business Development, Klus Pharma

Office of Operations (O2)
- Chair: Sihong Zhou, Sutro Biopharma
- Member: Linlin Xu, PhD, AstraZeneca; Min Lin, MS, Grail Bio

Membership (MEM)
- Co-Chair: Han Zhang, PhD, Senti Biosciences
- Member: Weihang Ji, PhD, Earli; Jay Lee, Acrobiosystems; Chunfeng Li, PhD, ITI; Di Yang, PhD, Earli Inc.

Public Relations & Communications (PRC)
- Co-Chair: Jingwen Tan, PhD, Alakos
- Co-Chair: Hesong Han, PhD, UC Berkeley
- Member: Yan Wang, PhD, ChemPartner; Suping Ren, MS, Aligos Therapeutics; Guanghui Han, PhD, BGI Americas

Alliance Management Committee (AMC)
- Co-Chair: Suzie Wu, PhD, Rulai
- Co-Chair: Dong Su, Gilead Sciences
- Member: Jessica Sun, PhD, ORIC Pharmaceuticals; Maggie Zhou, MS, Grail; Shaohua Xu, PhD, Eureka Therapeutics; Di Yang, PhD, Earli. Inc.

Science & Technology Committee (STC)
- Co-Chair: Ken Zhang, PhD, AssemblyBio.
- Co-Chair: Xiang Yi, PhD, Denali Therapeutics
- Member: Wenfeng Xu, PhD, Hengenix; Haixia Wang PhD, Allogene Therapeutics; Hao Shao, PhD, University of California, San Francisco; Weijie Lan, PhD, Walking Fish Therapeutics; Qi Hao, PhD, Calico

International Collaboration Committee (ICC)
- Co-Chair: Qiang Gan, PhD, Thermo Fisher Scientific
- Member: Tim Tian, PhD, Bio-CMC Advisory, Chengya Liang, MD, PhD, MBA, Natera; Bo Lian, PhD, Gilead Sciences; Wenhui Gao, MS, WuXi Biologics; Haixia Wang PhD, Allogene Therapeutics; Chenling Xiong, PhD, MD, Denali Therapeutics

Business & Career Development Committee (BCD)
- Co-Chair: Liping Meng, PhD, Gilead Sciences
- Co-Chair: Yuying (Kate) You, PhD, JD, Morrison Foerster LLP
- E-Club Chair: Huijun Zhou, PhD, Stanford University
- Member: Yiyuan Yin, PhD, Alamar Biosciences, Inc.; Yan Qi, PhD, JD, Morrison Foerster LLP; Kay Tong, MS, Apollomics; Danielle Lee, MS, CGL Partners, Inc.; Maggie Zhou, MS, Grail; Zhuoting Tan, Promelogix

Social Life Committee (SLC)
- Co-Chair: Yangzhong Tang, Eikon Therapeutics
- Co-Chair: Michael Xie, PhD, Teledyne ISCO
- Member: Li Wang, Arcus; Xuefeng Wang, ASC Therapeutics; Lucy Liu, Stanford University; Suping Ren, MS, Aligos Therapeutics

Regional Representatives
- East Coast Representative: Li Feng, PhD, JD, Finnegan
- Southern California Representative: Yiwen Li, NantHealth
- China Coordinator: Shiming Xu, PhD, Zhejiang University

Web Master:
Michael Lin, Pink Trumpet Associates

Accountant
Yao Long

Graphic Designer
Xiaojun Li



CABS 2020 EC Awards

2020 Distinguished Leadership Awards

Distinguished Leadership Award recognizes EC members for more than 3 years of service as Chairs or Co-Chairs at CABS EC Committees. Each awardee receives a complimentary life time membership and free passes to all CABS activities for 5 years starting from December 2020.

Yuying (Kate) You
BCD Co-chair

Dong Su
AMC Co-chair

Han Zhang
MEM Co-chair

Huijun Zhou
E-Club Chair

2020 Outstanding Service Awards

Outstanding service Award recognizes the outstanding services performed by EC members during the 2019-2020 term. Each awardee receives 2-year complimentary CABS membership, or a free pass to 2022 BioPacific Conference for life time member.

Min Lin
(O2)

Key Tong
(BCD)



Ying Wang
(AMC)

Guanghui Han
(PRC)

Chengya Liang
(ICC)



Wenhui Gao
(ICC)

2020 COVID-19 Donation Campaign Award

Xu Chen
AMC Advisor

Jingwen Tan
PRC Co-chair

2019 BioPacific Conference Special Contribution Award

This award recognizes extraordinary contributions to CABS 2019 BioPacific Conference

• Xu Chen, MS, MaxVision Biosciences • Frank Hu, PhD, Sentieon • Suzie Wu, PhD, Rulai • Su Dong, PhD, Gilead Sciences • Chenling Xiong, MD, PhD, UCSF • Maggie Zhou, PhD, Grail • Yao Yu, MS, Merck • Hui Liu, PhD, Medtronic • Jingwen Tan, PhD, Alakos • Hesong Han, PhD, UC Berkeley • Han Zhang, PhD, Senti Biosciences • Wenming Zhang, PhD, Stanford

2021 BioPacific Conference Organizing Committee

- **Carrie Wang, MD,** Chair, 2021 BioPacific Conference; President-elect, CABS; VP Preclinical, ARC Medical Device,
- **Yang Tian, PhD,** President, CABS; Senior Research Scientist, Gilead Sciences
- **Yan Wang, PhD,** CABS Board Member, Executive Director of Business Development, Kelun Pharmaceutical Research Institute
- **Xu Chen, MS,** Advisor, CABS Alliance Management Committee; Business Manager, MaxVision Biosciences
- **Sihong Zhou,** Chair, CABS Office of Operation; Scientist, Sutro Biopharma
- **Jingwen Tan,** Co-Chair, CABS Public Relations and Communications Committee; Sr. Manager, Allakos
- **Hesong Han, PhD,** Co-Chair, CABS Public Relations and Communications Committee; Postdoc fellow, UC Berkeley
- **Yuying (Kate) You, PhD, JD**, Co-Chair, CABS Business and Career Development Committee; Patent Attorney, Morrison & Foerster LLP
- **Liping Meng, PhD,** Co-Chair, CABS Business and Career Development Committee; Sr. Research Scientist, Gilead Sciences
- **Suzie Wu, PhD,** Co-Chair, CABS Alliance Management Committee; CFO, Rulai
- **Ken Zhang, PhD,** Co-Chair, CABS Science and Technology Committee; Staff Scientist, Pharmacyclics, an AbbVie Company
- **Guanghui Han, PhD,** Member, CABS Public Relations and Communications Committee; Director, BGI Americas
- **Yan Wang, PhD,** Member, CABS Public Relations and Communications Committee; Principal Scientist, ChemPartner
- **Shaohua Xu, PhD,** Member, CABS Alliance Management Committee; Research Scientist, Eureka Therapeutics
- **Su Dong, MS,** Co-Chair, CABS Alliance Management Committee; Sr. Associate Scientist, Gilead Sciences
- **Qiang Gan, PhD,** Co-Chair, CABS International Collaboration Committee; Staff Scientist, Thermo Fisher Scientific
- **Xiang Yi, PhD,** Co-Chair, CABS Science and Technology Committee; Scientist, Codexis
- **Kay Tong,** Member, CABS Business and Career Development Committee, MA, Sr. Director, Quality Assurance, Apollomics
- **Michael Xie, PhD,** Co-Chair, CABS Social Life Committee; Sales Representative, Teledyne ISCO
- **Yan Qi, PhD, JD,** Member, CABS Business and Career Development Committee; Associate, Morrison Foerster LLP
- **Suping Ren, MS,** Member, CABS Public Relations and Communications Committee; Scientist, Aligos Therapeutics
- **Jessica Sun, PhD,** CABS Alliance Management Committee; Director, ORIC Pharmaceuticals
- **Xuefeng Wang, PhD,** Member, CABS Social Life Committee; Senior scientist, ASC Therapeutics
- **Weixing Chen, MS, MD,** President, Gracious Life Foundation
- **Fang Xi, PhD,** Managing Partner, Button Capital

Graphics and Websites:

- **Xiaojun Li,** Graphic Design/Website Design
- **Michael Lin,** Website Design & Support, Pink Trumpet Associates

2021 BIOPACIFIC CONFERENCE - Virtual

AGENDA

Theme: Passion for Better Medicine

Time: 8:30 am - 4:30 pm, PDT, October 30, 2021

** The official working language of the conference is English*



8:30 AM – 8:50 AM	**Breakout Room Networking**
Morning Session I	**Session Chair: Carrie Wang**
8:50 AM – 8:55 AM	**Welcome Remarks** Carrie Wang, MD, President-Elect of CABS and 2021 BioPacific Conference Organizing Committee Chair
8:55 AM – 9:00 AM	**State of the Society** Yang Tian, PhD, President of CABS
9:00 AM – 9:35 AM	**Keynote 1: Traffic of Cas9-gRNA Between Cultured Human Cells Mediated by Cell-Cell Contact** Randy Schekman, PhD, Professor, Department of Molecular and Cell Biology, UC Berkeley ***2013 Nobel Prize for Physiology or Medicine***
9:35 AM – 10:00 AM	**CABS K. Fong Award in Life Sciences** **Fireside Chat, Presenter:** Kenneth Fong, PhD, Chairman, Kenson Ventures LLC **Awardees:** John O. Link, PhD, Former VP, Gilead Sciences, Inc. (Retired) Xian-Ping Lu, PhD, Founder, Chairman and CEO, ChipScreen BioSciences Co.
10:00 AM-10:25 AM	**K. Fong Award Speech: Reshaping Biotech Landscape in China** Xian-Ping Lu, PhD, Founder, Chairman and CEO, ChipScreen BioSciences Co.
10:25 AM – 10:50 AM	**K. Fong Award Speech: Lenacapavir: A Twice-Yearly Dosed First-in-Class HIV Capsid Inhibitor** John O. Link, PhD, Former VP, Gilead Sciences, Inc. (Retired)
Morning Session II	**Session Chair: Kate You**
10:50 AM – 11:20 AM	**Cancer Immunotherapy Trends and Highlights in the Post-Checkpoint Inhibitor Approval Era** Gary Starling, PhD, CSO, Xyphos Biosciences, Astellas Pharma Inc.
11:20 AM – 12:00 PM	**Panel Discussion 1: IP Considerations and Investment trends for Life Sciences** Session will cover intellectual property considerations for life science transactions, investment stories of new technologies, and discussions on a new company structure. **Moderator:** Janet Xiao, JD, PhD, Partner, Head of China Life Sciences, Morrison & Foerster LLP **Panelists:** Chuck Comey, Partner, Morrison & Foerster LLP Sean Cao, MBA, PhD, Managing Director, CBC Group Neil Desai, PhD, Founder & CEO, Aadi Bioscience, Inc.
12:00 PM – 12:30 PM	**Breakout Room Presentations** **Room 0: How to Choose Key Reagents for CAR-T Cell Therapy Development** Teng Peng, PhD, Technique Application Manager, ACROBiosystems **Room 1: Effective Use of Science in the FDA Regulatory Process** Bethany Hills, Partner, Morrison & Foerster LLP Keunbong (KB) Do, JD, PhD, Associate, Morrison & Foerster LLP

	Room 2. Precise and Efficient Non-viral CRISPR Gene Editing Solutions Lumeng Ye, PhD, Sr. Scientist, GenScript USA Inc.
	Room 3: Humanized Models for Improved Preclinical Discovery and Assessment of Novel Immunotherapies Jenna Frame, PhD, Manager, Scientific Communications & Marketing, Biocytogen Boston Corp.
	Room 4: Atomic-resolution cryoEM and Its Impact on SBDD Larry Jin, PhD, COO, Wuxi Biortus Biosciences Co., Ltd.
	What's Ahead for the Biotech Industry: Another Wave or Low Tide? Michael Zhao, Co-founder, Q Bay (Boston)
	Room 5: Clinical Study in the US and China Charles Li, MBA, MS, VP, Business Development, CR Medicon, a Pharmaron Company
	Next-Generation DMSO-Free & Serum-Free Cryopreservation for Cell Therapy Manufacturing and Processing Xiaoxi Wei, PhD, Co-founder & CEO, X-Therma Inc. User Affiliate at Lawrence Berkeley National Laboratory
	Room 6: Future of Targeted Therapies in Lung Cancer Sanjeev Redkar, MBA, PhD, President and Co-Founder, Apollomics Inc.
	Room 7: Opportunities and Challenges in the Development of an Innovative Clinical Research Platform Sophia Kan, Director of Marketing Strategy, GoBroad Healthcare Group Alex J. Zhang, PhD, Chief Scientific Advisor, Hanhai International Inc.
Afternoon Session I	**Session Chair: Ken Zhang**
12:30 PM – 1:05 PM	**Keynote 2: Towards Universal Druggability** Greg Verdine, PhD, Professor, Chemical Biology, Harvard University
1:05 PM – 1:35 PM	**How We Use Stem Cells and Genomics for Guiding Precision Medicine** Joseph C. Wu, MD, PhD, Director of Stanford Cardiovascular Institute and Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University
1:35 PM – 2:05 PM	**Designing Better Molecules Faster and with Less Expense: Illustrations of the Transformative Impact of Physics-Based Modeling Combined with Machine Learning** Matt Repasky, PhD, SVP, Life Sciences Products, Schrödinger Inc.
Afternoon Session II	**Session Chair: Jenen Tan**
2:05 PM – 2:35 PM	**The COVID-19 Pandemic: A Status Report** Arthur Reingold, MD, Professor and Head of the Division of Epidemiology at the School of Public Health, UC Berkeley
2:35 PM –3:15 PM	**Panel Discussion 2: Strategic Partnerships & Financing Trends for the Biotech Industry** **Moderator:** Cheni Kwok, CLP, PhD, Managing Partner & Founder, Linear Dreams LLC **Panelists:** Edward Harrington, MBA, CFO, Genentech Guo-Liang Yu, PhD, CEO, Apollomics Inc. Dewan Zeng, MBA, PhD, Head of Search and Evaluation, Business Development, BeiGene, Ltd. Cariad Chester, Partner, TCG Crossover "TCG X"
3:15 PM – 3:45 PM	**FDA Experience and Regulatory Considerations on Companion Diagnostics and Cancer Early Detection Test** Sharon Liang, MD, RAC, PhD, VP, Regulatory Affairs and Quality Affairs, Burning Rock Dx, LLC
3:45 PM – 4:00 PM	**A World-Class Healthcare Technology Innovation Platform at Hong Kong Science Park** Carrie Ling, PhD, Assistant Director of Business Development (InnoHK), Hong Kong Science and Technology Parks Corporation (HKSTP)
4:00 PM – 4:05 PM	**Conference Adjourned**
4:05 PM – 4:30 PM	**Breakout Room Networking**

Keynote Speaker

Berkeley
UNIVERSITY OF CALIFORNIA

Randy Schekman, PhD
Professor
2013 Nobel Laureat

Traffic of Cas9-gRNA Between Cultured Human Cells Mediated by Cell-Cell Contact

Abstract:
A challenge in genome editing in vivo is to devise an efficient means of delivering editing functions, preferably by a vehicle that evades immune detection. We sought a means to deliver Cas9 and a gRNA enclosed within an natural extracellular vesicle as a vehicle for efficient and targeted gene editing. Cas9 was expressed in a donor cell tethered noncovalently to an integral membrane protein, CD63, enriched in exosomes. Exosomes highly enriched in Cas9 and a gRNA were isolated by buoyant density. Isolated exosomes were incubated with reporter cells containing an integrated copy of N-luciferase behind a site which when edited would allow the expression of luciferase. In a control experiment, expression of the Cas9/gRNA construct directly in the reporter cell elicited a 60-70 fold increase in luciferase expression. Exosomes containing a similar level of Cas9 elicited no more than a 50% increase above the background of luciferase. The same was true of conditioned medium containing Cas9-exosomes and even of donor and acceptor cells incubated together separated by a vesicle-permeable membrane in a transwell chamber. In contrast, donor and acceptor cells cocultured to near confluence showed a 60-fold increase in luciferase expression. Transfer of Cas9 appears to be mediated by open-end membrane tubular connections, likely dependent on membrane fusion at the point of junction between a tubule from one cell and the target. A molecular dissection for the requirements for this transfer may permit the development of an efficient means for targeted delivery of Cas9/gRNA.

Bio:
Randy Schekman, PhD. is a Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, and an Investigator of the Howard Hughes Medical Institute. He studied the enzymology of DNA replication as a graduate student with Arthur Kornberg at Stanford University. His current interest in cellular membranes developed during a postdoctoral period with S. J. Singer at the UC Diego. Among his awards are the Gairdner International Award, the Albert Lasker Award in Basic Medical Research and the Nobel Prize in Physiology or Medicine, which he shared with James Rothman and Thomas Südhof. He served as the Editor of the Annual Reviews of Cell and Developmental Biology and as Editor-in-Chief of the Proceedings of the NAS and eLife. Schekman leads an effort with major philanthropic support to identify and fund basic research on the mechanisms of Parkinson's Disease initiation and progression (https://parkinsonsroadmap.org).

Schekman's laboratory investigates the mechanism of vesicular traffic in the secretory pathway in eukaryotic cells. Currently the lab investigates the mechanism of biogenesis of extracellular vesicles including how small RNAs are sorted for secretion in exosomes and the means by which these vesicles are internalized and function in target cells.

Keynote Speaker

HARVARD UNIVERSITY

fog·pharma

LifeMine

Greg Verdine, PhD
Professor, President, CEO

Toward Universal Druggability

Abstract:
A frustratingly elusive goal of drug discovery has been to reach a state of advancement at which all disease-driving targets are capable of being drugged, i.e. to achieve universal druggability, with biological and medical criteria being the sole determinants of which targets are prosecuted. Recent advances in the discovery of HeliconTM peptides – conformationally constrained alpha helical peptides – suggest this new modality represents a true contender toward enabling the majority of human proteins to be drugged. Progress toward the discovery

of HeliconTM peptides will be presented, along with lessons learned on building a powerful new modality drug discovery company.

Bio:
Gregory Verdine, PhD. is an award-winning university educator, pioneering scientist and innovator, life science entrepreneur, venture capitalist and successful biotech company-builder. Verdine is an originator of STEMgenesis, a new model for fostering community economic and intellectual growth through the convergence of philanthropy, workforce development, and institution creation. In a distinguished academic career spanning three decades at Harvard University and Harvard Medical School, Verdine reinvented the teaching of organic chemistry to focus intensively on its fundamental connectivity to biology, and he founded two fields of science that meld basic research and new medicines discovery: chemical biology, the pursuit of chemistry in the service of uncovering the mysteries of biology; and new modalities, the discovery and development of novel structural classes of therapeutics.

In his academic research, Verdine made fundamental discoveries into how living organisms manage their genomes, tagging them for cell-type specification, and conducing search-and-destroy operations for cancer-causing abnormalities. He invented a powerful new class of therapeutics termed stapled peptides, which enable intervention into diseases previously considered "undruggable." Hundreds of laboratories worldwide now conduct basic and translational research on stapled peptides, and an optimized stapled peptide pioneered at Harvard is currently in Phase II clinical development for the treatment of blood-borne cancers.

Verdine has been among the most active and successful entrepreneurs translating academic research into new medicines. As an academic founder at Harvard and a Venture Partner at several prominent life science investment firms, he is responsible for the creation of ten biotechnology companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals (acquired by Celgene) and WaVe Life Sciences. These companies have succeeded in gaining FDA approval for three breakthrough medicines and have multiple additional candidates in development. He moved beyond company ideation and creation into company-building and management at WaVe Life Sciences, Warp Drive Bio, and currently FOG Pharmaceuticals and LifeMine Therapeutics.

Verdine's concept of STEMgenesis took form with his founding and inaugural Presidency of the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy, which together aim to promote the creation of a vibrant life science industry on Cape Ann Massachusetts through coordinated establishment of a world-class ocean-based genomics research entity and an educational institution that trains high school graduates for rewarding careers in biotechnology.

Verdine's contributions to science and society have been recognized by numerous honors and awards, including his being named a Fellow of the Royal Society of Chemistry, and a Fellow of the American Association for the Advancement of Science. He is the recipient of a Presidential Investigator Award, the Nobel Laureate Signature Award, and the Award for Excellence in Chemistry in Cancer Research.

Verdine received a BS. and PhD. in chemistry from St. Joseph's University and Columbia University, respectively, and he is the recipient of honorary degrees from Harvard University and Clarkson University.

XYPHOS

Gary Starling, PhD
CSO

Cancer Immunotherapy Trends and Highlights in the Post-Checkpoint Inhibitor Approval Era

Abstract:
Immune checkpoint blockade has proved to be a highly successful therapeutic approach to fight cancer. The breadth of cancer types that respond to anti-PD-1 blockade has highlighted how well a reactivated immune system is able to kill cancer cells, leading in many cases to long term responses and cures. The success of checkpoint blockade, especially targeting the PD-1/PD-L1 pathway, has led to approval of multiple monoclonal antibodies with many others in development. Despite this success, it is clear that a large number of patients and multiple cancer types do not respond to PD-1 pathway inhibitors. Research across academia and the biopharmaceutical industry is continuing to identify new therapeutic approaches to treat checkpoint blockade-non responsive cancers. This talk will highlights some of these approaches including biomarkers to aid in patient selection, combinations of immune therapies, and novel modalities.

Bio:
Gary Starling, PhD. has focused his career on the Discovery and Early Development of Biologics therapeutics in large and small biopharmaceutical companies.

His PhD. studies in Immunology at the Christchurch School of Medicine, University of Otago, New Zealand where he studied NK cells and made mAb against leukocyte surface antigens. Following post-doctoral work in Immunogenetics at the Fred Hutchinson Cancer Center in Seattle, WA, and subsequent studies on Dendritic Cell maturation in Christchurch, New Zealand, Gary began his career in the BioPharmaceutical industry at Bristol-Myers Squibb in Seattle working on extracellular domains of leukocyte antigens as targets for monoclonal antibodies (mAb). He worked on Discovery stage small molecule

therapeutics at BMS in Princeton NJ, before moving to CuraGen, a Genomics-based biotech in the New Haven, CT area. At CuraGen, Gary headed up the Inflammation group, and had Project Management and Collaboration Management responsibilities for Biologics Programs. He moved to California in 2005 to join PDL BioPharma, a company that pioneered humanization of mAb, to head up their Autoimmune Diseases group. PDL BioPharma spun out Facet Biotech, where Gary was Senior Director of Research with responsibilities for Translational Oncology (including Empliciti, now approved for treatment of Multiple Myeloma) and led a preclinical Autoimmune Disease mAb program. Following the acquisition of Facet Biotech by Abbott Labs, Gary became Director, Oncology Biologics, and formed and led the Costimulation Early Biology Unit, establishing the company's Immuno-Oncology program. On joining Merck, Gary headed up the Therapeutic Area Biology and Pharmacology group before taking responsibility for the Discovery Biologics group where he had responsibility for a portfolio of monoclonal antibody therapeutics in multiple disease areas. Most of the therapeutics brought into early development were in the area of immuno-oncology, where Merck built on the emergent success of Keytruda. His group was also responsible for translational studies which identified biomarkers of response to Keytruda. Treatments for Infectious Diseases and Cardiovascular disease were also moved into development and have shown proof-of-concept in clinical studies. He has recently departed Merck for a soon to be disclosed company.

Gary has published more than 60 scientific papers, book chapters and patents and has been an invited speaker in conferences with topics ranging from Biologics Drug Discovery, Immuno-Oncology and Oncology Biologics. He has lectured Masters-level students on Cancer Immunotherapy, and developed programs at Merck and Abbott Labs teaching internal audiences Drug Discovery with a focus on Biologics.

GILEAD

John O. Link, PhD
Former VP (Retired)

Lenacapavir: A Twice-Yearly Dosed First-in-Class HIV Capsid Inhibitor

Absdract:

Lenacapavir (LEN, GS-6207)) is an investigational small-molecule first-in-class inhibitor of HIV capsid function and if approved will become the first drug targeting a viral capsid. As a structural protein, the HIV capsid protein (CA) is unlike traditional HIV enzyme or receptor targets. Uniquely, LEN disrupts multiple HIV replication steps by interfering with CA monomer protein-protein interactions during capsid assembly, disassembly, and nuclear trafficking. With picomolar antiviral potency and low pharmacokinetic clearance, LEN is more potent and less frequently dosed than currently approved HIV drugs and through its novel mechanism of action retains high activity against strains resistant to other antiretroviral (ARV) classes. A Phase 2/3 clinical trial (CAPELLA) of twice-yearly injected LEN with an oral lead-in showed viral load <50 copies/mL at week 26 in 81% of heavily treatment-experienced people living with HIV (PWH) with multi-drug resistance when added to an optimized background ARV regimen. In a Phase 2 clinical study in treatment-naïve PWH (CALIBRATE), LEN dosed subcutaneously every 6 months as part of a combination regimen led to high rates of virologic suppression (93% with HIV-1 RNA <50 copies/mL at week 28). Due to these promising results, a Phase 3 clinical study to assess the safety and effectiveness of long-acting LEN for HIV pre-exposure prophylaxis (PrEP) has been initiated in people at risk of acquiring HIV (NCT04925752). To discover LEN, we utilized small-molecule library synthesis, structure-guided design informing single-molecule synthesis, and multiple metabolic blocking strategies. Failures, successes, learnings, and course alterations over the fifteen-year journey in the discovery and ongoing development of LEN will be presented. In summary, twice-yearly lenacapavir holds promise in foundational approaches to HIV treatment and prevention with the goal of ending the global HIV epidemic.

Bio:

John O. Link, PhD. has 30 years of experience in discovering and developing drugs as a medicinal chemist and project leader. John received his PhD in Chemistry under the direction of EJ Corey at Harvard University working on CBS reduction chemistry and a novel synthesis of amino-acids, now named the Corey-Link Reaction. John elucidated the inhibition mechanism of the immunosuppressant drug CellCept® along with the enzymatic mechanism of its target, inosine monophosphate dehydrogenase at Syntex/Roche Palo Alto. At Celera John worked in inflammation and antiviral areas with three compounds entering clinical trials. John was a Vice President of Medicinal Chemistry at Gilead Sciences and led the project teams that discovered the hepatitis C NS5A inhibitors ledipasvir and velpatasvir (Harvoni® Epclusa®) and continued as the project leader through Phase I clinical trials. The NS3/4a protease inhibitor drug voxilaprevir was discovered in his group (Vosevi®). John is co-inventor on those three approved drugs. He is also a co-inventor and was a project leader on the first-in-class twice-yearly dosed Capsid inhibitor lenacapavir that is in multiple late-stage clinical trials for HIV treatment or prevention. John was awarded the American Chemical Society's 2015 "Heroes of Chemistry Award" for his contributions to the discovery of Harvoni®, and in 2017 received the inaugural "Male Ally" award from the "Women at Gilead" employee resource group.

Stanford University

Joseph C. Wu, MD, PhD
Professor

How We Use Stem Cells & Genomics for Guiding Precision Medicine

Abstract:
Immune Heart disease is the most significant cause of morbidity and mortality in the industrialized world. Recent technological advancement has enabled the generation of patient-specific and disease-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro. These iPSC-CMs carry all the genetic information from the individuals from whom they are derived. Here I will discuss recent advances in this technology and how it may be used for elucidating mechanisms of rare inherited cardiovascular diseases, for drug discovery, and for precision medicine.

Bio:
Joseph C. Wu, MD, PhD. is Director of Stanford Cardiovascular Institute and Simon H. Stertzer, MD, Professor of Medicine and Radiology at Stanford University. Dr. Wu received his MD from Yale University and PhD (Molecular & Medical Pharmacology) at UCLA. He is board certified in cardiology.

His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop "clinical trial in a dish" concept, and (iv) implement precision medicine for prevention and treatment of patients. Dr. Wu has published >400 manuscripts with H-index of 97 on Google scholar. He is listed as top 1% of highly cited researchers by Web of Science (2018, 2019).

Dr. Wu has received National Institutes of Health (NIH) Director's New Innovator Award, NIH Roadmap Transformative Award, American Heart Association (AHA) Innovative Research Award, Presidential Early Career Award for Scientists and Engineers (PECASE) given out by President Obama at the White House, AHA Established Investigator Award, Burroughs Wellcome Foundation Innovation in Regulatory Science Award, AHA Merit Award, and AHA Distinguished Scientist Award.

Dr. Wu serves on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee, AHA National Board of Directors, and Scientific Advisory Board for the Keystone Symposia. Dr. Wu is an elected member of American Society of Clinical Investigators (ASCI), Association of University Cardiologists (AUC), American Institute for Medical and Biological Engineering (AIMBE), American Association for the Advancement of Science (AAAS), American Association of Physicians (AAP), and National Academy of Medicine (NAM).

We Discover New Drugs 微芯生物 CHIPSCREEN

Xian-Ping Lu, PhD
Chairman & CEO

Reshaping Biotech Landscape in China

Abstract:
China: the land of generic medicines in the past, is now emerging through harmonization of regulatory issues, high quality of manufacture, science-driven R&D activities, global IP and needs for affordable medicines from rest of world, which inevitably will offer great opportunity for China-based biotech moving forward into global play for unmet medical needs.

Bio:
Xian-Ping Lu, PhD. founded Shenzhen Chipscreen Biosciences, the leading drug discovery and development company based in China focusing on innovative small molecular therapeutics 20 years ago with a group of US-trained professionals. Previously he was Director of Research at Galderma R&D in Princeton until 2000, the year he became visiting professor at China's State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego around 1994.

Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his PhD. in Molecular Biology and MS. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his BS. degree in Biochemistry from Sichuan University.

With over 30 years of biomedical research and biotech/pharmaceutical experience in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science and The Lancet. He is the lead inventor of over 300 patented inventions in areas of small molecule therapeutics.

In the past 20 years, Dr. Lu has participated and promoted many reforms in regulatory environment, policy, and guideline of NMPA, reimbursement system of national health care, security and exchange of capital market, taxation and many others in China. He has been recognized as "China's New Drug Trailblazer" as well as winning various of prizes and recognitions from the industry and other institutions.

SCHRÖDINGER

Matt Repasky, PhD
SVP

Designing Better Molecules Faster and with Less Expense: Illustrations of the Transformative Impact of Physics-Based Modeling Combined with Machine Learning

Abstract:
The rise of machine learning and accurate, physics-based modeling have facilitated breakthroughs in preclinical drug discovery, enabling faster discovery of compounds with improved chemical properties at reduced cost relative to traditional methods. In this webinar three practical vignettes applying machine learning to active drug discovery programs are discussed covering small molecule pKa prediction, hit identification, and maintaining or boosting protein-ligand affinity through design-make-test-analyze (DMTA) cycles in lead optimization. Application of cutting-edge machine learning methods enables exploration of billion compound chemical spaces through interpolation. Combined with accurate, extrapolative physics-based methods through active learning, discovery is transformed enabling chemists to accurately evaluate far more ideas against a given hypothesis than from experiment alone. In hit discovery this facilitates examination of billions of purchasable compounds to identify novel, more potent hits at a rate greater than traditional docking or shape screening methods. Similarly, drastic expansion in chemical space and speed of hypothesis testing in DMTA cycles during lead optimization enabled by accurate free energy perturbation-informed machine learning provides chemists more shots on goal to identify molecules that better satisfy the target property profile.

Bio:
Matt Repasky, PhD. Senior Vice President of Life Sciences Products, Schrodinger Inc., joined the company in 2002. He received his PhD. in Chemistry from Yale University in the laboratory of Prof. William Jorgensen. Since joining the company as a scientific developer, he has held several management roles including product manager of the industry-leading docking application, Glide. Matt has published extensively in the area of structure-based virtual screening and has provided leadership in the development of software products in the areas of docking, pharmacophore modeling, conformation generation, and QSAR modeling.

燃石医学 Burning Rock Dx

Sharon Liang, MD, PhD, RAC
VP

FDA Experience and Regulatory Considerations on Companion Diagnostics and Cancer Early Detection Tests in Precision Oncology

Abstract:
New oncology drug development has entered the precision medicine era that combines targeted therapy with companion diagnostic devices. Utilizing biomarkers in clinical trials to enroll patients has dramatically helped to bring oncology drugs to patients earlier and faster. Up to date, FDA has approved 44 companion diagnostics (CDx) which include 42 of those as CDx for cancer patient treatment selection. FDA regulates CDx as molecular diagnostic medical devices with a unique regulatory pathway and different studies are required to demonstrate how the medical devices are validated. It is important for both drug and devices developers to understand the regulatory requirements during the product development and design appropriate analytical and clinical studies. In addition to cancer patient treatment management, cancer early detection tests are also getting more and more attention by the community. Detecting cancer earlier saves lives. Both opportunities and challenges exist in cancer early detection test development. FDA's regulatory considerations for cancer early detection tests will be discussed with a case study to help the understanding of the essential aspects during product development.

Bio:
Sharon Liang, MD, PhD, RAC, VP Regulatory Affairs and Quality Affairs at Burning Rock Dx, LLC. Before joining the current company, Dr. Liang was the Senior Director Regulatory Affairs at GRAIL, Inc. Dr. Liang was a genetics expert at FDA leading reviews of new and upcoming technologies in the Office of In Vitro Diagnostic Device and Radiological Health (OIR), at the Center for Devices and Radiological Health (CDRH). As a senior reviewer and Principal Scientist, she developed multiple guidance and articulated medical device policies, including copy number variation detection, companion diagnostics, direct-to-consumer tests, Next-generation- sequencing (NGS), bioinformatics pipelines for NGS data, Precision Medicine, targeted therapy, cancer screening. She is an expert in the regulatory submissions of PMA, 510(k), 513(g), Q-submissions for medical devices, and IND • NDA • BLA for companion diagnostics devices

in Precision Oncology. Dr. Liang was a member of the FDA activity steering committee for the Precision Medicine Initiative leading the bioinformatics working group. She received her PhD. in Human Genetics and MS. in Applied Statistics from Vanderbilt University, followed by a postdoctoral cancer research fellowship at NCI and was a Commissioner's fellow at FDA.

Berkeley
UNIVERSITY OF CALIFORNIA

Arthur Reingold, MD
Professor

The COVID-19 Pandemic: A Status Report

Abstract:

A The global COVID-19 pandemic that erupted in early 2020 has left no country or community untouched, affecting every aspect of life, including travel, trade, economic development and education. The extraordinarily rapid development and deployment of multiple COVID-19 vaccines that are safe and effective has enabled many wealthy countries and communities to blunt the impact of the pandemic, but low and middle income countries have generally been unable to acquire and administer doses of the vaccines to large segments of their populations. As the SARS-CoV-2 virus, the cause of COVID-19, continues to mutate and produce new variants, the threat to the health of communities globally remains a serious concern. The presentation will offer an update regarding the status of the pandemic and efforts to minimize its impacts.

Bio:

Arthur Reingold, MD, is Professor and Head of the Division of Epidemiology at the School of Public Health at the University of California, Berkeley. Among the projects he directs are the California Emerging Infections Program, including its surveillance for and studies of COVID-19 in the San Francisco Bay Area. Dr Reingold has authored or co-authored almost 400 research articles on diverse topics within the field of infectious disease epidemiology and has been the recipient of numerous awards, including election to membership in the National Academy of Medicine.

HKSTP

Carrie Ling, PhD
Assistant Dirctor

A World-Class Healthcare Technology Innovation Platform at Hong Kong Science Park

Abstract:

To develop Hong Kong as a hub for global research collaboration, a new innovation platform focusing on healthcare, artificial intelligence and robotics technologies in collaboration with world renowned institutions was established in Hong Kong Science Park in 2020. It aims to converge top-notch researchers from all over the world to conduct world-class and impactful collaborative research.

This healthcare technology innovation platform focuses on all types of healthcare research including (i) Novel therapeutics in eye and neurodegenerative diseases and oncology, (ii) Vaccine platform for infectious diseases, (iii) Stem cell and regenerative medicine, (iv) Advanced medical robotics and devices, (v) Next-generation disease diagnostics and monitoring, and (vi) Health data analytics. In this talk, Dr. Ling will present the latest development of this platform and introduce the funding programs and supports in biotech and medtech for scientists, researchers and entrepreneurs in HK.

Bio:

Carrie Ling, PhD. is currently an Assistant Director of Business Development (InnoHK), Hong Kong Science and Technology Parks Corporation (HKSTP). Her role is to drive the development of Hong Kong as the hub for global research collaboration funded by the Hong Kong Special Administrative region Government. She has been supporting the biotech and medtech start-ups in fund raising and commercialization of their innovation in collaboration with the stakeholders from universities, NGOs, industry and government.

Before joining HKSTP, she was a senior lecturer of Integrative Systems and Design at Hong Kong University of science and Technology. She is passionate about empowering one's creativity in science and technology through solving real-life healthcare problems and nurturing the next generation biodesign entrepreneurs in HK. In 2016, she initiated and organized the first a-week-long MedTech Hackathon with Stanford Biodesign and HKU Dreamcatchers in HK. As a technical lead of medical devices at HKSTP, she established the "Healthcare Devices Innovation Hub" at HK Science Park to provide

the one-stop service for the young device start-ups from ideation to prototyping.

She obtained her bachelor and PhD degrees in the Department of Mechanical Engineering at The University of Hong Kong and The Hong Kong Polytechnic University in 2002 and 2006 respectively. She pursued her orthopedic research training at University of Florida, Department of Orthopedics and Rehabilitation, after her doctoral degree for two years. From 2009 to 2011, she was a Postdoctoral Fellow at Stanford University, Department of Mechanical Engineering. She has authored/co-authored more than 50 papers in international journals and conference proceedings and one US patent in optic fiber flowmeter for biomedical use.

PANELISTS

Moderator

LINEAR DREAMS LLC.
直梦

Cheni Kwok, CLP, PhD
Managing Partner & Founder

Cheni Kwok, CLP, PhD. is a senior biopharmaceutical executive with broad operational expertise who has executed over 150 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm's engagements include a broad range of business and corporate development activities including managing business development teams, product and technology licensing, search & evaluation of products and technology platforms, merger & acquisitions, corporate strategy, portfolio planning, market and competitive intelligence, due diligence support for financing as well as valuation services for over 50 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan and Singapore. Selected list of clients of Linear Dreams include Heat Biologics, Inc. (NASDAQ: HTBX), Shanghai Henlius Biotech, Inc. (HKG: 2696), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), Immune-Onc Therapeutics, Inc., Anwita Biosciences, Inc. and GF Xinde Investment Management Co. Ltd..

As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK).

Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a PhD. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS).

Genentech

Ed Harrington, MBA
CFO

Ed Harrington, MBA. is Genentech's chief financial officer. He assumed this role in January 2016. Ed leads the Genentech and Pharma North America Finance organizations as well as the Genentech Site Services function. He is a member of the Genentech Executive Committee and the Global Pharma Finance Leadership Team.

Ed joined Roche in 2001 as finance director, U.S. Consumer Health in Nutley, New Jersey. Following this role, he was finance director, US Pharma Alliances, General and Administrative, Tech Services, IT in New Jersey from 2003-2006. Ed moved to Switzerland in 2006 as global head of Pharma Strategic Alliances and R&D Portfolio Controlling through 2009. He then joined Roche Canada as vice president and chief financial officer from 2010-2012.

In 2013, Ed moved to Roche China where he was vice president, Finance. In this role he was responsible for Finance, Procurement and Business Development.

Prior to joining Roche, Ed held both finance and accounting positions in companies including J. P. Morgan and Ernst & Young.

Ed received his bachelor's degree in accounting from Robert Morris University and an MBA in finance and international business management from Carnegie Mellon University.

Cariad Chester
Partner

Cariad Chester prior to joining TCG X, Cariad was a Managing Director at Aquilo Capital, where he led investments in biotechnology companies developing human therapeutics. Prior to Aquilo Capital, he served as a research scientist in the lab of Dr. Holbrook Kohrt at Stanford University. His research focused on understanding tumor-immune system interactions during cancer onset, progression, and treatment. He has authored or co-authored over 20 peer-reviewed manuscripts and presented research at conferences in Canada, the US, and China. Cariad has also worked in clinical trial management, helping to launch and coordinate phase I, first-in-human trials of investigational immunotherapeutic agents, and formerly operated a consulting practice advising early-stage companies on assay development and pipeline prioritization. Cariad received his BA. from Swarthmore College, where he double majored in Neuroscience and Comparative Religious Studies.

Dewan Zeng, MBA, PhD
Head of Search and Evaluation, Business Development

Dewan Zeng, MBA, PhD. is the Head of Search and Evaluation, Business Development at BeiGene. In her current role, she leads a team of business professionals to identify and evaluate innovative products and technologies to complement BeiGene's portfolio. She led the due diligence teams and supported transactions on several licensing deals including BeiGene's collaborations with Amgen and Novartis. She also served as the transition team lead for Amgen BeiGene collaboration, which consists of 3 inline products and 20 pipeline products. Prior to joining BeiGene, Dewan worked at Pfizer in early oncology development and clinical research, was Director of Clinical Research at Gilead and Director of Translational Research at CVT. In her 23 years of pharmaceutical career, she served as the global program lead on multiple Phase 1 to Phase 3 clinical programs and supported NDA submission and approval of three pharmaceutical products in US, Europe and China.

Dewan has BS degree in Biochemistry from Peking University, PhD in Biochemistry from University of Virginia, and MBA in Global Business Strategy from Cal State University East Bay. She completed her post-doctoral training at UCSF. Dewan lives in San Francisco Bay Area with her husband and two children.

Guo-Liang Yu, PhD
CEO

Guo-Liang Yu, PhD. is the global CEO of Apollomics Inc., an innovative therapeutics company devoted to curing cancer by combining immunology and other cancer fighting methods. Before Apollomics, Dr. Yu was the Executive Chairman of Crown Biosicence Inc., a publically-listed personalized oncology platform company with ~600 employees globally. Crown Bioscience was recently acquired by JSR for $400 million. He co-founded Epitomics Inc., an antibody biotechnology company, and served as Chairman and CEO for 10 years prior to its acquisition by Abcam for $170 million. During his tenure at Epitomics, spun-off Apexigen Inc., an immune-oncology therapeutics company. He was also a venture partner at OrbiMed Venture LLC.

Dr. Yu's success is driven by his scientific curiosity and passion for translating scientific discovery to real products. After graduating from Fudan University in Shanghai, China, he came to the United States in 1984 to pursue advanced studies. He obtained his PhD. from UC Berkeley, where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburn's lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery.

Dr. Yu later joined Dr. Frederick Ausubel's lab at Harvard University to pursue the question of how plants defend themselves against pathogens without an immune system, and identified the plant disease resistance gene. In 1993, when genomics was still in its infancy, Dr. Yu joined Human Genome Sciences Inc. as one of the first few senior scientists, identifying human gene targets for drug discovery. Among several important drug targets he studied was BLys, the first successfully genomic target for the development of a lupus antibody drug Benlysta, which was approved by FDA in 2010.

In 1998, Dr. Yu was attracted to identifying plant genes with economic value in agriculture and in bio-energy. He was Senior Vice President of R&D at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors, and ultimately identified several valuable traits such as enhanced crop yield, disease resistance, and drought tolerance. Dr. Yu has co-authored 43 peer-reviewed scientific articles that have been referenced by the scientific community over 6000 times. He is a co-inventor of more than 400 patents.

Dr. Yu is the founding president of the Chinese Biopharmaceutical Association (CBA) and serves on the boards of several professional organizations in the United States and China, including BayHelix, Chinese-American Bio/Pharmaceutical Society (CABS), National Foundation of Cancer Research, Ray Wu Memorial Foundation, and University of Pacific. Dr. Yu is generous in coaching young entrepreneurs, and he has co-founded a dozen startup companies in biotech and the healthcare sector, including Immune-Onc Therapeutics, Inc. in Palo Alto.

Moderator

MORRISON FOERSTER

Janet Xiao, JD, PhD
Head of China Life Science, Partner

Janet Xiao, JD, PhD. patent partner at Morrison & Foerster LLP and head of firm's China Life Sciences Group, focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. Chambers USA and Chambers Global recognize her as being highly sought after for patent prosecution and strategy mandates by innovators from around the world.

MORRISON FOERSTER

Chuck Comey, JD
Partner

Chuck Comey, JD. is a partner in Morrison & Foerster's Palo Alto office. Described by a client as "a real superstar able to handle even the most complex and important transactions" (Chambers), Chuck advises on M&A, venture capital and private equity financings, and joint ventures and strategic alliances, with a focus on transactions in the life sciences and technology sectors. Before relocating to Silicon Valley in 2010, Chuck opened and served as managing partner of the firm's Shanghai office from 2003 – 2010, and he also spent nine years in the firm's Tokyo office. He speaks and reads Mandarin.

Chuck has cultivated a strong market reputation for his transactional work. He has been recommended as a leading lawyer for M&A by Chambers Global since 2015, earning the distinction of "Expertise Based Abroad" for his work in China. He is also ranked Band 1 for California: Deals in Asia by Chambers USA.

CBC Group

Sean Cao, MBA, PhD
Managing Director

Sean Cao, MBA, PhD. is currently the Managing Director of CBC Group (formerly C-Bridge Capital), where he focused on the incubation and strategy of new companies. In 2017, Dr. Cao co-founded Everest Medicines, a biopharma company focused on developing innovative therapeutics in China and other Asian regions, and served as its CEO until February 2020. Dr. Cao is also the Chairman of NiKang Therapeutics, a US based biotech incubated by CBC in 2017. Prior to CBC, Dr. Cao was VP of Global Business Development at Simcere Pharmaceutical Group, responsible for the global BD strategy for Simcere, including licensing, acquisition, partnering and investment activities. Dr. Cao was also the President

and Board Director at Simcere of America, a wholly owned subsidiary of Simcere. Prior to that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi, where he led the externalization effort in Global R&D, and managed the evaluation of acquisition/in-licensing opportunities. Before Sanofi, Sean was an associate at New Leaf Venture Partners, a healthcare VC firm based in New York. Sean worked in the pharmaceutical and diagnostic industries for over eight years before joining New Leaf, first at Aventis, then at Johnson & Johnson. Sean holds a PhD. in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a BSc. in Microbiology from Nankai University.

Neil Desai, PhD
Founder, Chairman and CEO

Neil Desai, PhD. is the Founder of Aadi Bioscience, Inc. He was former SVP, Global R&D, Abraxis Bioscience; VP, Strategic Platforms, Celgene Corp; Inventor of the nab® technology, Abraxane® and ABI-009. He successfully led the Abraxane team through all development stages. He has over 25 years of experience in novel therapeutic delivery systems with over 100 issued patents, over 40 peer-reviewed publications and book chapters, and over 200 presentations at scientific meetings. He participated in FDA and EU Nanotechnology initiatives and was a member of the Steering Committee for the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer.

He holds a MS and PhD. in Chemical Engineering from the University of Texas at Austin, USA, and a BS. in Chemical Engineering from the University Institute of Chemical Technology in Mumbai, India.

BREAKOUT ROOM PRESENTATIONS & SPEAKERS

Teng Peng, PhD
Technique Application Manager

How to Choose Key Reagents for CAR-T Cell Therapy Development

Abstract:
T cells engineered to express chimeric antigen receptors (CARs) anti-specific tumor associated antigen have shown remarkable success in the treatment of hematologic malignancies and revitalized the field of adoptive cell therapy. Five CAR-T cell therapy drugs have been approved by the FDA so far.

As a "living drug", CAR-T cells development involves a complicated process, including positive CAR detection, T cell subset identification, potency & safety profiling, and the others. Among them, the active ingredient of CAR-T drugs is CAR-positive T cells, which is called "cornerstone" in the quality control of cell therapy. In addition, successful CAR-T cells activation and expansion are critical indicators for the functionality of the final CAR-T cells product.

This talk would present the key reagents for the detection of CAR surface expression and CAR T-cells activation in the quality control and clinical stages of CAR-T cells development. We would specifically share our new product platform of star staining fluorescent site-labeled proteins for the detection of CAR surface expression by flow cytometry with high specificity and sensitivity.

Bio:
Teng Peng, PhD. has around 20 years of experience in pharmaceutical R & D at AstraZeneca and Merck with wide scope of expertise and knowledge in preclinical drug discovery, translational science, and early drug development. In addition, Teng has years of basic research and drug discovery experience in the disease areas of CV, diabetes, respiratory, and CNS. Teng earned her MS in Molecular Biology and PhD in Biochemistry. "

apollomics 冠科美博

Sanjeev Redkar, MBA, PhD
President and Co-Founder

Future of Targeted Therapies in Lung Cancer

Abstract:
Lung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. The five-year survival rates have improved only incrementally over the past four decades in comparison to other tumor types. The treatment of advanced and metastatic non-small cell lung cancer (mNSCLC) has changed dramatically in recent years due to advanced molecular diagnostics and the recognition of targetable oncogenic driver alterations. This has led to the development of very effective new targeted agents, and thus to a relevant progress in the treatment of oncogene-addicted mNSCLC. The use of checkpoint inhibitors in first line setting has resulted in an unprecedented improvement in the five-year survival rates. However, the vast majority of advanced NSCLCs become resistant to targeted treatments and eventually progress or metastasize in the brain. Successful development of rational combination therapies to reduce such metastases using robust predictive biomarkers will be the future toward managing mNSCLC over the coming decade.

Bio:
Sanjeev Redkar, MBA, PhD. is the President & Co-Founder of Apollomics Inc., a biotech company developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways. In his previous role, Dr. Redkar was SVP, Product Development at Astex Pharmaceuticals, an Otsuka company. Dr. Redkar has led the development of several oncology therapeutics though IND and global launch including Dacogen, Nipent and Mitozytrex. Additionally, Dr. Redkar worked on multiple drugs through their FIH submission and clinical trials that led to the buyout of Astex to Otsuka for close to a billion dollars. He has over 25 years of oncology drug development experience, over 25 peer-reviewed publications and 150 patents. Dr. Redkar earned his PhD. from University of Colorado, MBA from St. Mary's College of California, and Bachelor's at Indian Institute of Technology Bombay. Dr. Redkar is an Adjunct faculty and a Board Member at the University of the Pacific School of Pharmacy, Stockton, Advisory Board of University of Colorado, Boulder, Chemical Engineering Dept. and Board Member of EPPIC, an entrepreneurial biotech organization.

MORRISON FOERSTER

Bethany Hills, JD
Partner

Effective Use of Science in the FDA Regulatory Process

Abstract:
This breakout session will examine how the FDA is developing innovative approaches to regulation and the increasing importance of effectively using science and data in the regulatory process. Topics will include Emergency Use Authorizations and developments between the FDA and the US Patent and Trademark office as well as regulatory strategies for new technologies.

Bio:
As co-lead of the FDA Regulatory & Compliance practice at Morrison & Foerster LLP, **Bethany Hills, JD.** advises her life sciences and health tech industry clients on both pre- and post-market issues, including everything from FDA submissions and communication strategies to post-approval FDA and healthcare compliance and reimbursement issues. Her clients span the full range of FDA and healthcare regulated companies, including medical device and health tech, drug, combination product, diagnostic, biologic, and regenerative medicine, cosmetic, dietary supplement, and food industry businesses, and the investor groups focusing on innovation in these industries.

MORRISON FOERSTER

Keunbong (KB) Do, JD, PhD
Associate

Bio:
Keunbong (KB) Do, JD, PhD. leverages his industry experience and PhD. in biophysical chemistry to assist clients with U.S. and international IP strategies and patent prosecution, as well as

supporting our FDA clients. KB received his JD. from Harvard Law School. Prior to law school, KB worked at Samsung SDI as a leader of the Chemical-Mechanical Planarization (CMP) slurry development team and as a senior research engineer in the semiconductor materials development group. He earned his PhD. in biophysical chemistry from Stanford University, where his research focused on characterizing and engineering fluorescent proteins using various concepts and tools in molecular biology, biochemistry, and physical chemistry.

GenScript
Make Research Easy

Lumeng Ye, PhD
Sr. Scientist

Precise and Efficient Non-viral CRISPR Gene Editing Solutions

Abstract:
With the 4th approval on CAR-T therapy (Breyanzi) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment. The delivery of specifically designed CAR or T CR encoding component can be done by viral vectors, but with limitations like random insertions and complicated manufacture process. With the power of CRISPR, precise and efficient T cell engineering can be carried out in a non-viral, plasmid-free manner. At this talk, we will show how GenScript can efficiently manufacture sgRNA and DNA payloads for precise CAR/TCR KI in T cells. With this upgraded capability and recent advances in non-viral delivery, efficiently and precisely engineer T cells with minimal off-targets is becoming a reality.

Bio:
Lumeng Ye, PhD. an expert in molecular and synthetic biology. She received her PhD in Bio-engineering from Vrije Universiteit Brussel, Belgium, and did postdoc at Denmark Technical University.

BIOCYTOGEN

Jenna Frame, PhD
Manager, Scientific Communications & Marketing

Humanized Models for Improved Preclinical Discovery and Assessment of Novel Immunotherapies

Abstract:
The use of animal models in preclinical drug efficacy evaluations is limited by genetic differences between mouse and human drug targets. To overcome these limitations, humanized models have been developed for the evaluation of novel drugs for popular therapeutic targets. In this seminar, we will provide a comprehensive overview of the advantages of using various types of humanized models to discover and validate novel drug targets, including syngeneic mouse tumor models and humanized immune system mice. We will summarize how these models can mimic human immunity in the context of immunotherapy, and provide specific examples of the application for these models for assessing new therapeutics for popular immuno-oncology and inflammatory disease targets. In addition, the recent development of humanized immunoglobulin mouse models has further contributed to the field by allowing for the in vivo generation of fully human antibodies that accelerate and de-risk antibody drug research and development. Altogether, humanized mouse models can be used to accelerate preclinical research workflows to identify the best possible disease targets and drug candidates for future clinical success.

Bio:
Jenna Frame, PhD. has worked with mouse and zebrafish models in the hematology field for over 15 years at the University of Rochester and Harvard Medical School. At Biocytogen, Jenna helps provide researchers with the information they need to select quality animal models and other preclinical services to advance their research pipeline.

BIORTUS

Larry Jin, PhD
COO

Atomic-Resolution CryoEM and Its Impact on SBDD

Abstract:
Cryo-electron microscopy (cryoEM) is a biophysical technique that can be used to determine the 3-dimensional structures of biological macromolecules and assemblies. A resolution revolution has been happening in cryoEM in the last ~10 years, owing to the development of direct electron detectors and more effective computational image processing algorithms. Atomic-resolution structures are being determined at unprecedented speed, for drug-targets such as large protein complexes and membrane proteins, which have been difficult for traditional X-ray crystallographic approach.

I will discuss the advancements in both hardware and software which lead to the emerging atomic-resolution cryoEM and how cryoEM is re-shaping structure-based drug discovery (SBDD). Lastly, I will present our efforts at Biortus to make cryoEM accessible and affordable to the drug discovery industry.

Bio:
Larry Jin, PhD. serves as Chief Operating Officer of Wuxi Biortus Biosciences Ltd. Prior to joining Biortus, Dr. Jin was a co-founder and CEO of 3D BioPharma Inc., a company dedicated to structure-based drug discovery.

Dr. Jin got extensive biotech experience when he worked at Biogen in Boston and Ignyta in San Diego, where he was involved in drug discovery projects in both oncology and neuro-degenerative diseases.

Dr. Jin was a research associate professor at Burnham Institute of Medical Research from 2010-2014 and an assistant professor at University of Texas, Houston from 2005-2006. Dr. Jin completed his post-doctoral training in structural biology at Harvard with Prof. Stephen C. Harrison, after he got his PhD. in Molecular Medicine in 1999 from Cambridge University, England. He received his MS. in Molecular Biology from Chinese Academy of Sciences in1990. He received his BS. in Biology in 1987 from Peking University, China.

CR Medlcon
A PHARMARON COMPANY

Charles Li, MBA, MS
VP of Business Development

Clinical Study in the US and China

Abstract:
US and China have offered enormous opportunities for biopharmaceutical companies to develop new products and expand the market of approved products. In the new era of China biopharma development, more China-based emerging biotech companies are applying INDs and conducting clinical trials in US. Going global is a new trend for China biotech and this presents unique and exciting opportunities and challenges. Sponsors from either side need to gain deep understanding of the latest clinical trial landscapes in US and China. What's the main difference between US and China when conducting and managing clinical trials? How to plan and execute clinical programs smarter, faster and more efficiently by leveraging strengths from both sides? How to develop a solid strategy and best pathway to orchestrate clinical development across US and China to achieve trial development success and global market access will the discussed in this fifteen minutes presentation.

Bio:
Charles, MBA, MS. has over twenty years of working experience in drug research and development, possessing broad life science expertise including medicinal chemistry, radiochemistry, molecular imaging/diagnostics, protein therapeutics, and cell therapies for cancer and neurodegenerative diseases, ranging from discovery, translational to clinical development. Charles was a research scientist before his business profession, playing a variety of leadership roles in different organizations, both in the US and China, focusing on business growth strategy and market validation/penetration. Charles has led business development (sales and marketing) for multiple emerging biotechs and CROs for their critical global growth and is the driver of team building and resource-acquiring. Charles has actively played soccer for thirty years and an intelligent team player.

Sophia Kan
Director of Marketing Strategy,
GoBroad Healthcare Group

Opportunities and Challenges in the Development of an Innovative Clinical Research Platform

Abstract:
With the continuous implementation of Chinese national healthcare policies, the demand for new drugs is increasing. China's pharmaceutical industry plays a more prominent role in the national economy. The next decade will be a crucial period for China's new drug R&D to catch up with the western world. Clinical trial is the most time-consuming and most expensive step in the process of new drug development. At present, about half of the leading global pharmaceutical companies have CROs to carry out phase I - III clinical trials. Accordingly, China's clinical CRO services have risen rapidly to meet the high demand.

GoBroad Clinical Research Center has created a closed-loop system of clinical discovery, basic scientific research, technology transfer, and clinical application to comprehensively accelerate the transformation of clinical research. Relying on rich clinical expert resources, it has built a clinical driven innovative research platform, constructed dedicated research hospitals, and established an international leading clinical research center, IIT and difficult disease diagnosis and treatment center, and translational research center. GoBroad focuses on the trends of innovative drugs R&D in China and explores collaboration to expand clinical research capabilities.

As the foundation of GoBroad Healthcare Group's strategy, the company currently operates 7 research hospitals as exclusive clinical research institutions (sites), with a total of more than 600 beds. It has established a long-term strategic partnership with world-class hospitals and medical schools, and is committed to becoming a leading clinical research medical group in the world.

Bio:
Sophia Kan, Director of Marketing Strategy at GoBroad Healthcare Group. Ms Kan is an expert in Phase I - IV clinical trial operations and global regulatory affairs. Prior to GoBroad, Ms Kan was the Chief Executive Officer and Chief Strategy Officer at eStart Medical Technology Co., a leading clinical CRO service provider in China.

Michael Zhao
Q Bay (Boston) Co-founder

What's Ahead for the Biotech Industry: Another Wave or Low Tide?

Abstract:
Biotech is experiencing opportunities while many other sectors are becoming more pessimistic about the outlook for their businesses as the global pandemic continues to spread. The understanding and finding treatment or preventive solutions to diseases including COVID-19 has focused intense government, media, and public attention on science and medicine, reinforcing the perception that biotech acquisitions and partnerships represent a good investment. In an effort to understand worldwide biotech trends in the context of the COVID-19 crisis, Q Bay Center will join the discussion about the financial performance of small and midsize biotechs and the venture capital opportunities and challenges.

Bio:
Michael Zhao started Longwood Biology Inc with friends after graduating from Harvard Medical School in 2014, aiming to develop effective and low toxic anti-neurodegenerative drugs from small molecules, and translating bench work to bedside therapies for Alzheimer's disease. He founded LB Ventures in 2016 for early-stage startups in the biotech industry. LB Ventures invests globally across the spectrum of healthcare companies including pharmaceuticals, medical devices and medical services, focusing on developing and expanding early-stage life science and technology companies with strong potential to achieve global success in their markets. In 2017 he established the team of HLT Inc with friends which is a medical analytics company focused on analytical solutions, pharmaceutical market access and real world evidence through a better use of AI technology, data acquisition and analytics. In 2020, he joined Q Bay as a partner focusing on the platform to support innovation and connect entrepreneurs. Q Bay is committed to accelerating start-up development by leveraging technology resources and finance accessibility, while building a diverse community.

Xiaoxi Wei, PhD
Co-founder & CEO
User Affiliate at Lawrence
Berkeley National Laboratory

Next-Generation DMSO-Free & Serum-Free cryopreservation for Cell Therapy Manufacturing and Processing

Abstract:
The regenerative medicine field is rapidly advancing, with many pivotal trials underway. As the field moves into large scale commercial manufacturing, cryopreservation becomes an ever more critical component for ensuring maximum efficacy and long shelf-life during end-to-end production. However, the potency and yield of fragile cell types, such as induced pluripotent stem cells and genetically modified cell-based immunotherapies, are significantly reduced post-cryopreservation due to ice damage and genomic and in vivo toxicity associated with current cryoprotectants (e.g. DMSO). These issues further limit the realization of off-the-shelf advanced regenerative medicine products, such as those being developed in allogeneic cell therapy and tissue engineering.

X-Therma applies convergent biomimetic nanoscience to solve this unmet need in biopreservation, pioneering a novel chemistry that is inspired by natural antifreeze protein and developed with modern drug discovery methods. Our fully synthetic molecules are non-toxic, chemically stable, and exhibit surprising dual ice control function, superior to antifreeze proteins and 500x more effective than non-colligative small molecule cryoprotectants. The resulting product XT-ThriveTM is a DMSO-, serum-, and protein-free and a completely chemically-defined cryopreservation solution.

Third party validations have demonstrated superior post-thaw cryopreservation outcomes for both cell viability and functionality with a variety of engineered cell lines and therapeutic cell-based products. XT-ThriveTM is extremely process-friendly and can be directly plugged into current workflows without requiring any specialized instrumentation, replacing the leading DMSO based cryopreservation solutions. Empowered by negligible toxicity, XT-ThriveTM removes bottlenecks for large batch production and enables a highway of premium quality cell products for the many patients in need.

Bio:
Xiaoxi Wei, PhD. is an entrepreneur and chemistry professional in the area of supramolecular assembly and biomimetic nanoscience. Her PhD. work demonstrated the success of developing synthetic transmembrane nanopores with distinguished selectivity applying biomimetic and supramolecular chemistry principles. She is the inventor of X-Therma's core technology based on hyper-effective ice prevention materials. She founded X-Therma Inc. in 2014 to develop a state-of-the-art biopreservation formulation that incorporates a first-in-class hyper-effective (500x) and non-toxic proprietary antifreeze polymer. She led the X-Therma team as an industrial User at The Molecular Foundry, Lawrence Berkeley National Laboratory from 2015 to 2018 and gained multiple recognitions internationally and nationwide. She is the principal investigator of multiple SBIR awards to develop breakthrough cryoprotectants enabling complex tissue/organ cryopreservation. She is experienced in business development and fund raising and managed international procurement projects in various industries while completing her PhD. study. She was a major author of 8 peer-reviewed research papers before founding X-Therma.

Announcing 2021 CABS K. Fong Award in Life Sciences

*The Chinese American Biopharmaceutical Society (CABS) K. Fong Award Committee is very pleased to announce that **John O. Link, PhD.** and **Xian-Ping Lu, PhD.** are the winner of the 2021 CABS K. Fong Award in Life Sciences for research, entrepreneurship, and innovation.*

John O. Link, PhD

John O. Link, PhD. has 30 years of experience in discovering and developing drugs as a medicinal chemist and project leader. John received his PhD in Chemistry under the direction of EJ Corey at Harvard University working on CBS reduction chemistry and a novel synthesis of amino-acids, now named the Corey-Link Reaction. John elucidated the inhibition mechanism of the immunosuppressant drug CellCept® along with the enzymatic mechanism of its target, inosine monophosphate dehydrogenase at Syntex/Roche Palo Alto. At Celera John worked in the inflammation and antiviral areas with three compounds entering clinical trials. John was a Vice President of Medicinal Chemistry at Gilead Sciences and led the project teams that discovered the hepatitis C NS5A inhibitors ledipasvir and velpatasvir (Harvoni® Epclusa®) and continued as the project leader through Phase I clinical trials. The NS3/4a protease inhibitor drug voxilaprevir was discovered in his group (Vosevi®). John is co-inventor on the patents disclosing these three approved drugs. Under his leadership, Gilead moved three small molecule HCV inhibitors from discovery to FDA approval. Since their approval from 2014 to 2016, those HCV drugs have cured 1.5 million HCV patients globally by mid-2017. He is also a co-inventor and was a project leader on the first-in-class twice-yearly dosed Capsid inhibitor lenacapavir that is in multiple late-stage clinical trials for HIV treatment or prevention. John was awarded the American Chemical Society's 2015 "Heroes of Chemistry Award" for his contributions to the discovery of Harvoni®, and in 2017 received the inaugural "Male Ally" award from the "Women at Gilead" employee resource group.

Xian-Ping Lu, PhD

Xian-Ping Lu, PhD. is Chairman, CEO of Shenzhen Chipscreen Biosciences Co. LTD. Dr. Lu founded Shenzhen Chipscreen Biosciences 20 years ago with a group of US-trained professionals. He built Chipscreen Biosciences into a leading Chinese drug discovery and development company focusing on innovative small molecular therapeutics. ChipScreen is probably the only truly innovative, vertically integrated biopharma company in China. Using active compounds as probes to characterize proteome functions, this novel approach allows small molecules to be systematically screened as new therapeutic targets, enhancing the ability to create target-specific chemical drugs. The chemical genomics approach led to the discovery of Chidamide, a highly selective histone deacetylase HDAC inhibitor. The approval of Chidamide also broke China's reliance on foreign imports for innovative drugs. The out-licensing of its overseas patents brought Chipscreen large milestone payments and made Chidamide the first original Chinese drug authorized for use in the US and other countries. This sets a precedent for China to change from a drug imitator to a creator.

Previously Dr. Lu was Director of Research at Galderma R&D in Princeton until 2000, the year he became visiting professor at China's State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University. He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego around 1994.

Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of

California in San Diego, followed by research fellowship at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his PhD. in Molecular Biology and MS. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his BS. degree in Biochemistry from Sichuan University.

With over 30 years of biomedical research and biotech/pharmaceutical experience in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings. He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science and The Lancet. He is the lead inventor on over 300 patented inventions in areas of small molecule therapeutics.

In the past 20 years, Dr. Lu has participated and promoted many reforms in regulatory environment, policy, and guideline of NMPA, reimbursement system of national health care, security and exchange of capital market, taxation and many others in China. He has been recognized as "China's New Drug Trailblazer" as well as winning various prizes and recognitions from the pharmaceutical industry and other institutions.

About the CABS K. Fong Award in Life Sciences

CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.

Candidates must be nominated by an active member of CABS. Selection criteria are based on candidate's accomplishments in life sciences and contribution to the life science community, including one or all of the following:

- *Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or research reagent/equipment markets.*
- *Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.*
- *Significant contribution to the CABS community and promotion of international collaborations in life sciences.*

About Kenneth Fong, PhD

Kenneth Fong, PhD. has spent the last 32 years in the biotech industry after completing his academic pursuit in biomedical research.

He is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was sold to Becton Dickinson in 1999 and Ken has continued his career as a Venture capitalist with Kenson Ventures that he founded. He has since cultivated more than 10 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 10 companies that are worth more than $3 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-07) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-13). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2006, he was involved with establishing the Fong Optometry and Medical library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.

Ken obtained his PhD from Indiana University and his BS from San Francisco State University.

* * *

Past recipients of CABS K. Fong Awards

2019: John V. Oyler, PhD. *Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.*

2018: Yuling Luo, PhD. *Founder, CEO and Chairman of Alamar Biosciences, and* ***Dr. Guoliang Yu****, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.*

2017: Yinxiang Wang, PhD. *Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana®, the first small molecule oncology drug specifically targeting cancer cells that was completely developed in China, and* ***Dr. Edgar Engleman,*** *for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.*

2016: Gerald Chan, PhD. *co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.*

2015: Irving Weissman*, PhD. of Stanford University, for his pioneering work in stem cell research.*

2014: Ge Li, PhD. *Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China and* ***Dr. Hing L. Sham****, formerly of Abbott for his leading role in the discovery of life- saving HIV protease inhibitors, ritonavir and lopinavir.*

2013: Peter Hirth, PhD. *Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market and* ***Dr. Jean Cui,*** *formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.*

2019-2021 Selected CABS Activities

2019 BioPacific Conference

2019 BioPacific Conference, also the 21st Chinese American BioPharmaceutical Society (CABS) Annual Conference, was successfully held on June 22, 2019 at San Mateo Marriott, San Mateo, California. The theme of this year's conference was "Pursuing Science for Cure". The Conference attracted a record numbers of nearly 700 attendees, representing over 250 companiesand organizations from the US, China and other regions. A total of 57 sponsors showcased their new services and products in the exhibition hall.

The conference included 8 podium talks and 3 panel discussions led by industry and academic leaders. The topics covered the scientific R&D and business trends of the biopharmaceutical industry. Experts from the forefront of the life science innovation shared and discussed the current status and future prospects of cancer therapeutics, treatment design for the cure of HIV, new strategies in the field of neurodegenerative disease drug development, precision medicine for individual patient treatment, virtual drug development to FDA approval,

as well as other hot topics including CIFUS, export control reform, recent decisions affecting life sciences investment and licensing, investment opportunities and strategies in the field of biomedical, life sciences and other high tech industries.

Dr. Yang Tian, the Chairman of conference organizing committee, gave welcome speech and introduced the agenda. Dr. Yan Wang, the President of CABS, opened with the State of the Society speech, highlighting the activities and achievements of CABS in the past year.

Dr. Ken Fong presented the 2019 CABS K. Fong Award to John V. Oyler, Founder and CEO of BeiGene, in recognition of his leadership and outstanding achievements in biomedical business and drug development. After receiving the award, Mr. Olyer, shared his life story, his deep understanding of drug development over the years and his vision about the future of biopharma industry.

Dr. Ron Mazumder from Genentech introduced the research and translational study of biomarkers in the field of cancer therapy. Dr. Jason Liu, CEO of WuXi Diagnostics, focused on the demand of companion diagnostics in cancer drug development and WuXi's commitment to precision medicine based on data-driven clinical insights. Dr. Romas Geleziunas, Executive Director of Gilead, presented Gilead's treatment design for human immunodeficiency virus (HIV). Neurodegenerative diseases are one of the most difficult diseases in biopharmaceutical research and development, and there is currently no effective clinical treatment plan. Dr. Zachary Sweeny from Denali Therapeutics presented their company's new approach to drug discovery in this area. Professor Shivaani Kummar from Stanford University described how to use predictive biomarkers and genomes to help individualized precise drug treatments and how to design better early clinical trials to help making key decisions in later trials. Dr. Leonard Post, Chief Scientist of Vivace Therapeutics, reviewed the amazing story of Talazoparib, a new PARP inhibitor, from virtual drug development to FDA approval.

Joseph Benkert, former Assistant Secretary of Defense for Global Security Affairs during Bush and Obama administrations, currently Senior Advisor in Morrison & Foerster's National Security practice group, introduced the latest developments in CIFUS, export control reform, and recent decisions affecting life sciences investment and licensing. He also discussed his advices with other panelist regarding the corresponding strategies for cross-border investment in the life sciences field.

In addition, the three panel discussions have also held hot topics on intellectual property rights in the biomedical field, related laws and regulations, and cross-border investment collaborations, next wave of cancer treatments, innovation and collaborations in drug research and development. The audience actively interacted with the speakers throughout the meeting. The 2019 BioPacific Conferencewas a successful gathering of life science professionals from all over the world to share the knowledge to pursue science for cures.





2019 Gene Therapy Workshop

Gene Therapy Workshop, co-organized by CABS (the Chinese American Biopharmaceutical Society) Science & Technology Committee and CCBEA (California Chinese Biotech/Biopharmaceutical Entrepreneur Association), was successfully held on October 5, 2019 at Hanhai BioLabs in Burlingame, CA. Nearly 150 professionals attended the workshop that included 5 talks given by gene therapy experts from both industry and academia. The topics covered lentivirus gene therapy, Adeno-Associated Virus (AAV) gene therapy manufacturing, and non-viral gene deliver using nanoparticles.

Dr. Yan Wang, the Past President of CABS gave welcome remarks and introduced CABS briefly. Dr. Shenjiang Liu, the President of CCBEA, introduced the history of CCBEA and reviewed the main activities of CCBEA in the past years. Dr. Xiang Yi and Dr. Ken Zhang co-chaired this workshop.

Dr. Gary Li, the founder and CEO of ALSTEM, presented the history of viral gene therapy, from concept formation and early clinical attempts to recent successful clinical applications. He discussed the use of lentivirus as a gene delivery tool and provided details of different generations of the lentivirus packaging systems. Lentiviral approach was recognized as a valuable tool in both ex-vivo and in-vivo clinical applications such as, β-thalassaemia, cerebral adrenoleukodystrophy, and chimeric antigen receptor-T cells.

Dr. Haifeng Chen, CEO of Virovek, Inc., focused on the development of AAV in large scale of manufacturing and process for clinical application. Two major challenges for AAV manufacturing are its productivity and infectivity. Dr. Chen tackled these problems by introducing an artificial intron in the AAV vector and developed a serum free BAC-TO-AAV system with high infectivity and productivity. Under his leadership, Virovek now has the capacity to provide purified AAV vectors exceeding 1 x 10^17 vg scale per production run.

Dr. Niren Murthy, Professor in the Department of Bioengineering at UC Berkeley, shared non-viral technologies and biomaterials developed by his lab for gene delivery. He assembled a delivery vehicle termed CRISPR-Gold that composed of gold nanoparticles complexed with the Cas9/gRNA ribonucleoprotein (RNP), donor DNA, and an endosomal disruptive polymer. The CRISPR-Gold enabled the correction of DNA mutation that causes Duchenne Muscular Dystrophy (DMD) in mdx mice via homologous DNA recombination.

Dr. Kee-Hong Kim, Senior Vice President, Manufacturing & Technical Operations of Tenaya Therapeutics, talked about manufacturing clinical AAVs at scale for gene therapy. He discussed strategic questions for AAV manufacturing, considerations for clinical AAV manufacturing and regulator's expectation for gene therapy CMC, as well as suggestions for developing a start-up gene therapy company. His suggestions included talent acquisition in AAV manufacturing, compliance of gene therapy CMC, and strategic positioning of products in the market.

Finally, **Dr. Shengjiang Liu,** Chief Scientist and Head (VP) of Global Pathogen Safety of Product Supply-Biologics of Bayer Pharmaceuticals, discussed the hopes and challenges in gene therapy. He talked about the history of gene therapy, current ongoing over 3,000 clinical trials, global market, as well as regulation and reimbursement issues. He emphasized the challenges of gene therapy such as purification efficiency, and manufacturing capacity but also reminded the audience of all the opportunities when we entered the modern era of gene therapy.

CABS 2020 Investor Forum

2020 CABS Investor Forum was held on January 15th of 2020 in conjunction with JP Morgan Healthcare Conference. This forum is a highly popular workshop that explores topics related to US/China cross-border issues in the biopharmaceutical industry, during the JP Morgan week.

This Investor Forum featured a morning session and an afternoon session. The morning session was joined by China- and US-based investors, business development executives, and entrepreneurs. The topics focused on the trends, opportunities and challenges in capital investment, business development and M&A, in US and China Biopharma. The afternoon session was annual Innovation Roadshow presented by the Entrepreneurship Club (E-Club) of CABS in Morrison & Foerster's San Francisco office. The Innovation Roadshow served the dual purposes of celebrating the entrepreneurship tradition of the CABS community and providing a debut stage for emerging entrepreneurs of the community. Eight start-up companies had been selected to showcase their innovative technologies.

2020 CABS Entrepreneurship Club Proud to Present Innovation Roadshow During JP Morgan Week

The Entrepreneurship Club (E-Club) of CABS, together with eChinaHealth, hosted its annual Innovation Roadshow on January 15, 2020 at Morrison & Foerster's San Francisco office. The roadshow featured eleven emerging companies in the healthcare industry that are founded by members and friends of the CABS community.

In her opening remarks, **Dr. Huijun Zhou**, Program Chair of the E-Club, introduced the vision of the CABS as the gateway linking life sciences professionals and organizations in the U.S. and Pacific Rim countries. The E-Club serves this vision by bringing together investors, entrepreneurs and service professionals in the CABS community in year-round workshops, panel discussions, and social mixers.

More than two hundred people registered for the event, many of whom chose to attend the roadshow among concurrent satellite meetings of the JP Morgan conference.

Thank You for Your Donations to Fight against COVID-19

CABS, a 501(c)3 non-profit organization, launched one online donation campaign from March 22, 2020@1:00 pm to June 22, 2020@8:00pm, to meet a shortage of personal protective equipment (PPE) in US hospitals. This brought a big risk to our healthcare workers to combat COVID-19. CABS had decided to call for your donations to buy PPE and other essential supplies. Let's team up to fight against COVID-19!!!

From March 22 to April 23, we received $30,660 and delivered 5500 surgical masks, 3460 KN95 masks, 100 protective suits, 1237 Coverall Protective Gowns, and 2000 face shields to 35 hospitals around the US. Totally, we successfully organized 8 batches of PPE delivery to different hospitals.

Thanks to all CABS donors for your cash donation and PPE donation! Many thanks to our volunteers for logistic operations!






CABS
LOVE
Marketing Dept.


CABS
LOVE


CABS
LOVE

Broad Spectrum Antiviral Remdesivir for the Treatment of Emerging Viral Infections with High Outbreak Potential

CABS successfully held its first webinar via Zoom conference on February 27th, 2020. Dr. Yang Tian, President of CABS, moderated this webinar. This webinar attracted more than 700 attendees from the U.S., China and other countries.

In this webinar, Dr. Danielle Porter, Director of Virology from Gilead Sciences, presented the preclinical development of remdesivir; Dr. Tomas Cihlar, VP of Virology from Gilead Sciences, discussed the clinical development of remdesivir and ongoing clinical trials for COVID-19, which has caused more than 3,000 deaths globally since January 2020.

Finally, we sincerely thank Dr. Porter and Dr. Cihlar for giving a timely talk to CABS community, CABS EC volunteers for their efforts organizing this event, and Zoom Conference and Beijing Wellbeing Foundation for technical support and free Zoom access.

COVID-19 Clinical Treatment and Research

CABS held online webinar named "COVID-19 Clinical Treatment and Research" on March 24th, 2020. The Society of Chinese American Physician Entrepreneurs (SCAPE) and Fudan University Health Care Alumni Association co-organized this event.

Dr. Wenhong Zhang, a professor in Huashan Hospital in Fudan University, shared his highly valuable knowledge to fight against current global pandemic. Dr. Jinwen Ai also answered questions from audience and Yifan Wang assisted the logistics of the talk.

This webinar attracted >10,000 audiences around the globe (see audiences mapping below), with peak simultaneous audiences >7,000. This is the most popular event organized by CABS. Many physicians and nurses who are fighting COVID-19 at frontline expressed their appreciation to Dr. Wenhong Zhang and his team, for sharing their first-hand experiences. The knowledge may help to save both patients and healthcare workers' life.

Executives Roundtable - Career Advancement and Leadership

On June 14, 2020, CABS and Intellipro Group were co-hosted Executives Roundtable online. This webinar invited four distinguished guest speakers including Dr. David Gravett, VP of strategy at Poly-Med Inc., Dr. Jen Majeti, head of global collaborations and general manager (China) at Erasca Inc., Dr. Selena Yuan, director of global talent management at Gilead sciences Inc. and Dr Zhenhai Shen, CEO of NewBay pharma Inc. The topic was the transition from realm of scientific research to the real business world.

The speakers shared views about major areas of career transitions from R&D to business operations, the impact of COVID-19 on business operations and management, as well as the differences between working in big corporations and small companies or startups. The webinar was moderated by Ross Fensterwald, the strategic partnership leader of IntelliPro Group and was processed in the form of Q&A.

To sum up, we are living in challenging times and challenges always bring opportunities. Companies that are willing to have the flexibilities to embrace changes and have global perspectives will gain competitive advantages over their competitors.



COVID-19 Pandemic Requires Global Collaborations

On May 2, 2020, the Chinese American Biopharmaceutical Society (CABS) successfully hosted a webinar entitled "COVID-19 Pandemic Requires Global Collaborations". The event was co-organized by the Gracious Life Foundation (GLF). Five frontline physicians and scientists who are combating COVID-19 gave a series of mini-talks followed by a panel discussion on current COVID-19 pandemic.The webinar attracted more than 700 healthcare and life sciences professionals from around the globe, including many frontline physicians and nurses who are fighting the disease themselves (see below audience map).

Challenges after Re-opens: Will Massive Testing be Our Safeguard?

On June 20, 2020, CABS successfully hosted the webinar "Challenges After Re-opens: Will Massive Testing be Our Safeguard? ". The event was co-organized by the Gracious Life Foundation (GLF).

Six invited panelists include industry leaders from Bio-Techne, BGI Group, Twist Bioscience, as well as academic researchers from University of Texas, Carnegie Mellon University, and Johns Hopkins University. Presentations and panel discussions focused on existing and innovative tests, including high throughput PCR testing, antibody testing and point-of-care testing capabilities, and their potentials on achieving widespread availability of rapid, efficient COVID-19 diagnostics.

The webinar attracted more than 130 life sciences professionals to attend.

Contact Tracing and Control of COVID-19 Community Spread

On August 22, 2020, CABS successfully hosted a webinar entitled "Contact Tracing and Control of COVID-19 Community Spread". This webinar was co-organized with Chinese American Semiconductor Professional Association (CASPA) and Gracious Life Foundation (GLF). The webinar attracted about 150 attendees from around the world.

Dean Michael Lu, from UC Berkeley School of Public Health, started with a keynote speech on "Innovating Solutions to Covid-19". Dr. James Mu, from Providence Regional Medical Center, Seattle, Washington, presented "COVID-19 Contact Tracing, Therapeutics and Vaccine Development". Professor Zuo-Feng Zhang, from UCLA Fielding School of Public Health, presented "Epidemiology and Control of COVID-19 Pandemics: Current Status & Future Trends". Our last speaker, Professor Po-Shen Loh, from Carnegie Mellon University, presented "An Alternative Paradigm for App-based Contact Tracing which Incentivises Adoption".

Dr. Michael Prelip, Professor and Chair, Department of Community Health Sciences, UCLA, moderated a panel discussion among the four speakers and discussed important questions related to disparity in healthcare access and strategies to encourage behavioral change and vaccination.

Antibody Drug Conjugates

On August 29, 2020, CABS successfully hosted a webinar on Antibody Drug Conjugates (ADCs).

With the accelerated approval of Trodelvy in 2020, nine antibody drug conjugates now on the market have truly proven their potential. During the webinar, five experts from Seattle Genetics, Sutro Biopharma, Genentech, and Eli Lilly delved into the pioneering development of ADC from its early discovery to manufacturing CMC and clinical study. The speakers also emphasized the recent application of the ADC in fields other than oncology.

The webinar attracted more than 200 attendees from the biotech and pharmaceutical communities.

2021 CABS Investor Forum

CABS presented 2021 Investor Forum at 4:00 pm-7:30 pm (PST) on January 13th, 2021, in conjunction with the JP Morgan Healthcare Conference.

Sixteen China- and US-based investors, business development executives, and entrepreneurs joined the forum. The topics focused on the trends, opportunities and challenges in capital investment, business development and M&A, next generation of innovative therapeutics. The impact of COVID-19 and US-China relationship on Biopharma investment was also discussed.

The Investor Forum had three panel discussions: next wave of Innovative therapies, trends of capital raising in biotech and pharma, and building cross-border life science companies.



COVID-19 Small Molecule Drug Discovery

CABS Science & Technology Committee organized the "COVID-19 Small Molecule Drug Discovery" webinar at 1:30-5:30 pm (PST) on February 27th, 2021.

COVID-19, caused by SARS-CoV-2, is a global health and economic catastrophe. The main protease (Mpro) and the papain-like protease (PLPro) are essential for SARS-CoV-2 replication and thus are the compelling targets for small molecule anti-COVID-19 drug discovery. Regulating proteases in other viruses has been proven to be a successful pathway in the treatment of virus-caused diseases such as HIV and HCV. With progress on the understanding of these protein structures by collecting their high quality X-ray data, drug design and medicinal chemistry are being accelerated by computational tools to efficiently identify potent small molecule inhibitors. It's of great hope that some breakthrough discovery may be achievable in a short period of time through integrated efforts and collaborations.

Five scientists and specialists presented the online webinar about COVID-19 small molecule drug discovery. They presented their recent discovery and thoughts about how we should conquer this virus.



Ongoing Battle against COVID-19: Therapeutic Antibody Development

CABS held online webinar named "Ongoing Battle Against Covid-19: Therapeutic Antibody Development" at 4:30-7:00 pm (PST) on April 24th, 2021. Bayhelix, CABS, and CBA co-organized this scientific virtual seminar.

To combat Covid-19, the pharmaceutical industry has sped up drug discovery on neutralizing antibodies as a therapeutic option. While vaccination is underway in many countries, there is an increasing concern over newly emerging variants of the virus. What have we learned from therapeutic antibody development in this pandemic? How can we accelerate antibody development to fight the variants? What should the pharmaceutical industry do to win the battle against Covid-19 virus globally?

This joint-force seminar discussed the progresses and challenges in COVID-19 therapeutic antibody development. Five highly experienced industry leaders/scientists shared their experiences, progresses and thoughts.







2021 CABS Virtual Job Fair

On August 7th, 2021, CABS hosted a free virtual Job Fair on Zoom. The Job Fair attracted more than 30 participating companies that intended to recruit talents for 150+ positions at different levels in the US, mainland China and Hong Kong. About 200 people including PhD. students and postdoctoral fellows from universities such as Stanford, Berkeley, UCSF, NYU, Columbia and professionals in the Bio/Pharmaceutical field registered for this event.

During the event, each participating company had an individual room to interact with potential candidates. About ten featured companies also showcased their visions and discussed open positions in the show room for interested attendees. Organizing Committee received very positive feedback from both participating companies and job seekers.









HELPING TO DRIVE INNOVATION AND GROWTH FOR A HEALTHIER TOMORROW

Innovation is at the heart of the life sciences industry. As partner to some of the leading life sciences innovators, MoFo supports your groundbreaking ideas and helps you discover the real-world solutions that will bring those ideas to life.

Subscribe to MoFo Life Sciences for the latest legal and business insights impacting the global life sciences community.

lifesciences.mofo.com

MORRISON FOERSTER

We are a purpose-driven company imagining a world without cancer.

At Apollomics, we let science drive our decision-making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.





- We are committed to the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.
- Our science-driven approach powers a pipeline of next-generation, combination, and pan-cancer therapies for patients globally.
- Dual Presence in the U.S. and China and Executing a "Dual" In-licensing Strategy.

We are an ideal partner for companies from the West interested in entering the China market, as well as companies from China interested in accessing international markets. We have established numerous strategic collaborations to increase our pipeline of assets, explore new treatment areas, and expand our global reach.

apollomics
冠科美博
apollomicsinc.com

BIOSYSTEMS Acro | *Where Proteins and Innovation Advance Biomedicine*

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostics.

The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. The firm's products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. The company is determined to become a cornerstone enterprise in the field of biomedical and health industry.

> 5,000 Customers

> 60 Countries

> 100,000 Scientists

Our Clients

Pharma | Biotech | Diagnostics | Vaccine | CRO | Academia

Products and Services

ACROBiosystems' catalog includes a comprehensive list of disease-associated biomarkers and drug targets from humans to other common species. Facing with the pandemic caused by SARS-CoV-2, ACROBiosystems has been tracking the most up-to-date genomic data of the virus and going full steam ahead on SARS-CoV-2 variants-related product development, including a collection of recombinant antigens, antibodies, ELISA kits and magnetic beads.



ACROBiosystems +1 800-810-0816(US / Canada) +86 400-682-2521(Asia & Pacific) techsupport@acrobiosystems.com 1 Innovation Way, Newark, DE 19711

BIOSYSTEMS Acro | Recombinant Proteins for Biopharma Industry

Human CD20 Full Length Protein

- HEK293 Cells & Insect Cells Expression
- Complete Conformation
- High Bioactivity



FGL1 : A Novel Immune Inhibitor of LAG-3

- HEK293 expressed
- More species and tags to choose
- Avitag™ Biotin-labeled available

NEW PRODUCT LAUNCH



MABSOL®Biotinylated Proteins

- Closest to Natural Conformation and Modification
- High Bioactivity & Detection Sensitivity
- High Batch-to-Batch Consistency



Suitable for Detection of CAR Expression

50% OFF FOR NEW CUSTOMER
CAR-T Target Proteins





>>>Flow cytometry validated and protocol offered<<<

ACROBiosystems is a leading manufacturer of recombinant proteins. We provide high-quality protein reagents and technical support to the biopharma community. Our catalog includes biotinylated proteins, immune checkpoint proteins, Fc receptor proteins, CAR-T cell therapy targets, biosimilar drug targets, anti-idiotypic antibodies, and quantitative analysis of mAb in serum.

ACROBiosystems Tel: +1 800-810-0816 order@acrobiosystems.com 1 Innovation Way, Newark, DE 19711 www.acrobiosystems.com

BIO INCUBATION PROGRAMME

HKSTP 香港科技園

"Make the next biomedical breakthrough with us"

Give your biotech venture a boost in this four-year programme that provides up to HK$6 million in R&D support, along with equipment, co-working spaces, lab services and regulatory support.

Scan for more details

MISSIONS

- To boost the growth and development of biomedical startups in Hong Kong
- To promote patient smart healthcare journeys
- To connect with industry stakeholders and partners
- To provide platforms for exploring local, regional and global opportunities

ELIGIBILITY

- A **HKSAR registered** startup company
- No more than **2 years** for local companies
- Own the IP(s) or should have the **freedom to operate the IP(s)**
- High-caliber companies working on advanced and cutting-edge **biomedical technologies**

BENEFITS



CO-INCUBATROS

AstraZeneca — *Focused on Integrated Oncology Solutions*

金域医学 KingMed Diagnostics — *Focused on Diagnostic Platform & IVD Products*

CONTACT US +852 2629 6869 incubio_enquiries@hkstp.org hkstp.org/incubio

INNOVATIVE SOLUTIONS TO ACCELERATE ANTIBODY DISCOVERY

Humanized Mouse Models

- Humanized Immune Checkpoint Mice
- Immunodeficient B-NDG Mice for Xenograft Studies
- Humanized Cytokine & GPCR Mice
- Humanized Tumor Cell Lines

Antibody Discovery

- Fully Human Therapeutic Antibodies, Surrogates, Anti-idiotype & Bispecific/Multispecific Antibodies
- Single B Cell Cloning Technology
- Best-In-Class Fully Human Antibody Mouse



Pharmacology Services

- Expertise in Efficacy Evaluation of Novel Therapeutics
- In Vitro Studies, In Vivo Assays, PK, PD, Toxicity Assessments

Gene Editing Services

- CRISPR/Cas9-Based Extreme Genome Editing (EGE™)
- ESC-Based Homologous Recombination (Large Fragments)
- Models or Cell Lines

OUR INTEGRATED SERVICES

百奥赛图
BIOCYTOGEN

ABOUT US

- 1,200+ Employees Worldwide
- 2,000+ Partners & Clients → 1,500+ ACADEMIC, 500+ INDUSTRIAL
- 9 of the TOP 10 Pharmaceutical companies use our models and/or services

OUR EXPERTISE

1,200 Strains of BIOMICE

10-20 FOLD
Increased Knock-In Efficiency with EGE™

820+ DRUG EVALUATION PROJECTS
Delivered Annually

INDUSTRY-LEADING
Single B Cell Screening Technology

View our models page and full catalog:

www.biocytogen.com

Hanhai (Wuxi) Life Science International Innovation Hub is located in Wuxi, Jiangsu Province. Strategically focused on biotechnology, medical devices, and precision medicine, it aims to accelerate life science companies with global and professional insights. It also provides customized services for enterprises to get access to overseas market.

WeChat

Gather global professional resources to provide one-stop entrepreneurial services.

Operating Resources	Financial Advisor	Lecture Trianing、Mentor Consulting	CFDA Consulting	Marketing	Multi-dimensional Business Development

Ecosystem	Global Innovation	Venture Capitals	Medtech Companies	Medical Resources
	San Francisco、Los Angeles、Munich…	>400	Large Domestic And Foreign Companies	Hospitals, Universities and Associations

biohub@hanhaizhiye.com

Jiangsu Wuxi (Huishan) Life Science and Technology Industrial Park（L-Park） is located at the heart of Yangtze River Delta.More than 200 life science companies have started businesss in L-Park, including WuXi AppTec, Bioduro, CASI, Genetron, Cellular Biomedicine, etc.

- **Convenient transportation** —— 40 mins to ShangHai
- **Attractive talent policy** —— 3-10 million RMB
- **Functional layout** —— GMPs, R&D public platform, independent labs,flexible office
- **Industrial investment fund** —— over 10 billion RMB

We provide

Workspace · Biomedical Lab · Incubation Acceleration · Funding

Exhibition · Service · Events · Mentors

Contact

info@hocsci.com

http://www.hocsci.com/

160 E Tasman Dr, San Jose, CA 95134

Follow us

CR MedIcon
A PHARMARON COMPANY

About CR Medicon

- High Quality Drug & Medical Devices Development in the U.S and China

We are a fast-growing, innovative Contract Research Organization (CRO) dedicated to providing high-quality clinical development services globally. With 700 staff, we are a full-service platform in China with a dedicated biometrics service platform in US. Our team is led by industry veterans with 15-25 years of experience. We have adopted Medidata technology platform globally, accredited in many Medidata products including Rave/Balance/CTMS/eTMF. Our team is highly proficient in CDISC implementation including CDISC CDASH/SDTM/ADaM. We can help you to make sure the same set of global standards and quality is implemented, meeting the requirements of both US FDA and China NMPA. If you are thinking about expanding your drugs or devices into China market, or if you are evaluating a biometrics CRO that can provide high quality services yet at the same time can be flexible enough, CR Medicon is your best choice.

Data Management & Biometrics Services in the U.S

We have a large Data Management and Biostatistics team with hundreds of successful study and submission experience in US and China. Our team is led by industry veterans with 15-20 years of experience. We use Medidata system for all of our US studies and about 75% of our China studies. Most of our studies are implemented using CDISC standards. Our biometrics team is ready to help you to conduct studies meeting international data and reporting standards no matter they are run in US or China.

Visit us : https://en.crmedicon.com **Email: biz@crmedicon.com**

CABS
Chinese-American Bio/Pharmaceutical Society
北美华人生物医药协会



CHINESE AMERICAN BIO/PHARMACEUTICAL SOCIETY (CABS)

For more information please visit:

Website: *www.cabsweb.org*

Mailing Address: 268 Bush Street, #1888, San Francisco, CA 94104, USA

General information: *Info@CABSweb.org*

Membership: *Membership@CABSweb.org*

Fundraising: *Fundraising@CABSweb.org*